



THE UNIVERSITY OF
SYDNEY

Curriculum Vitae

Professor Sinthia Bosnic-Anticevich

Degrees, qualifications

1992-1996 Doctor of Philosophy (University of Sydney)
1988-1991 B.Pharm(Hons) (University of Sydney)
AHPRA Registration number: PHA0001369164

Employment

2017 - current Professor, Woolcock Institute, Faculty of Medicine and Health, The University of Sydney and Local Sydney Health District
2013 - 2016 Associate Professor, Woolcock Institute, Faculty of Medicine and Health, The University of Sydney and Local Sydney Health District
2006 - 2012 Senior Lecturer in Pharmacy Practice, Faculty of Pharmacy, University of Sydney
2000 - 2005 Lecturer in Pharmacy Practice, Faculty of Pharmacy, University of Sydney
1998 - 1999 Senior Scientific Associate, Astra Zeneca Pty Ltd
1997 - 1998 Senior Clinical Research Associate
1996 - 1997 Clinical Research Associate, Astra Pharmaceuticals Pty Ltd
1992 - 1996 Part-time tutor, Faculty of Pharmacy, University of Sydney
1992 - 1996 Casual part-time Pharmacist, Soul Paterson's Pharmacy, Strathfield, NSW
1992 - 1996 PhD candidate, Faculty of Pharmacy, University of Sydney
1992 - 2005 Casual Community Pharmacist, Soul Patterson's Pharmacy, Strathfield, NSW

Current ongoing national/international leadership (not noted elsewhere)

2020 - ongoing President, Respiratory Effectiveness Group (International Appointment)
2020 - ongoing Chair of the Primary Care Special Interest Group of the Thoracic Society of Australia and New Zealand (National Appointment)
2020-ongoing Steering Committee, International Severe Asthma Registry (International Appointment)
2018 - ongoing Executive Committee of the Primary Care SIG of the European Association of Allergy and Clinical Immunology (International)
2017 - ongoing Chair of ARIA Australia (International appointment)
2017 - ongoing Executive Committee, Woolcock Institute of Medical Research
2017 -ongoing Chair, Woolcock Development Committee
2016 - ongoing Chair of Pharmacy Allergic Rhinitis and its Impact on Asthma (Pharmacy ARIA) (International Appointment)
2014 - ongoing Steering Committee, Optimum Patient Care- Australia (OPC Australia)
2013 - ongoing Team Leader, Quality Use of Respiratory Medicines, Woolcock Institute
2013 - ongoing Director of Development, Woolcock Institute of Medical Research
2013 - ongoing Director, Respiratory Effectiveness Group (International Appointment)

1. International reputation as a leading authority in the respiratory field

I have been recognized as a leading authority in the field of respiratory medicines use, recognised by my own professional colleagues and by colleagues in other health professions. This recognition has enhanced my ability to build partnerships and join ventures across health disciplines, both nationally and international, resulting in outcomes of mutual benefit to multiple health professions.

Evidence of my international reputation is exemplified through international invited talks, invitations to participate in international senior industry advisory boards and the impact of my research output on multidisciplinary global guidelines for the management of respiratory disease in practice.

Invited talks

I am recognised as a leading authority in my profession, in the management of chronic respiratory disease; in particular as it relates to the use of respiratory medicines in primary care. This recognition is exemplified through the number and nature of national and international talks that I have been invited to deliver to pharmacists, general practitioners and respiratory physicians in Australia, Europe, Asia, the Middle East, North and Central America; a total of 24 international invitations over the last 5 years (18 fully funded). The primary focus of these talks has been in respiratory medicine, in particular on the use of respiratory medicines by patients, and the role of primary health care providers in addressing the challenges of inhaler use in chronic obstructive pulmonary diseases.

Invitation to advise, consult and represent the profession

My authority as a leader in my profession is recognized by national and international stakeholders within the pharmaceutical industry. Over the past 5 years I have participated in 14 international advisory boards, in each case being the only pharmacist, amongst a multidisciplinary team of medical practitioners, practice nurses/community nurses, and at times health economists, regulators etc. for the purpose of providing expert profession-specific advice to help guide the companies in their strategic approach to particular initiatives, research investments or other topical matters of commercial and practice relevance. Individual companies with whom I have engaged are listed in my CV and include AstraZeneca, GSK, Mylan, Sanofi, Teva, Boehringer Ingelheim.

I am regularly consulted by my pharmacy and general practice colleagues. I am regularly asked to provide expert commentary to Australian Pharmacist and the Australian Journal of Pharmacy and am asked to represent the Pharmaceutical Society of Australia as a pharmacist and respiratory medicine expert at stakeholder meetings. I am regular contact with my general practice colleagues (including A/Prof Charlotte Hespe, RACGP and University of Notre Dame and Prof Jennifer Reath, University of Western Sydney) discussing matters of mutual interest in the delivery of respiratory care in the community.

Leadership in my profession through impact on clinical guidelines

My international reputation as a respiratory pharmacist is evidenced in the impact of my research on national and international guidelines for practice around respiratory medicines use. Following a series of novel findings relating to inhaler use over a number of years from 2004 onwards, a steady shift in guidelines for professional practice in asthma and COPD were observed. For example, prior to 2010, inhaler technique was cited 3 times and pharmacists were not mentioned in these guidelines. In the latest updates to GINA (2020) and GOLD (2020), inhaler technique is cited over 80 times and the role of the pharmacist highlighted throughout. My leadership in this area of research in pharmacy has led the way to a new generation of clinical inquiry in this field across the pharmacy and medical disciplines (further details of thought innovation described below).

Leadership through influence on publishing and funding

I am Associate Editor and on the Editorial Board of several high impact international respiratory journals including the European Respiratory Society Monograph and the European Respiratory

Review and within these roles I am primarily responsible for the peer review process of all submitted manuscripts associated with respiratory medicine use and/or pharmacy practice and primary care. This is evidence of leadership in my profession and recognised by my international multidisciplinary medical colleagues as I work with them to contribute to the strategic directions and decisions of these high impact journals.

I am invited to review 3-6 grants per year for international granting bodies including the Health Research Council of NZ, Asthma UK, Health Research Board (Ireland), Euro Regional Development Fund (EU). Most if not all of the grants that I have reviewed in the past have been applications from medically-led multidisciplinary teams; my invitation to review them reflects international recognition of professional leadership.

Media coverage

My authority as a leading respiratory medicines expert has resulted in my being invited to do media interviews, in both the medical, pharmacy (e.g. Australian Doctor, Respiratory Republic, Pharmacy News etc) and lay media. Over the last 5 years, I have made multiple appearances on television/radio/online/print media both nationally and internationally as well as the evening news. A recent example comes following the release of research exposing the high prevalence of reliever medication overuse by people with asthma in the community pharmacy (September 2019) and the important implications that this has for pharmacists and GPs in managing their patient with asthma. The radio and television interviews that I gave in August 2019, were estimated to reach over 2 million people and an Advertising Space Rate of over \$350,000, as determined by the media portal monitoring company, Isentia.

Current and proposed research interests

I am a respiratory research in the field of respiratory medicines use, with a particular focus on the role of medication use in the management of chronic obstructive pulmonary diseases in practice.

Over the course of my academic career I have been instrumental in establishing inhaler technique as a field of research, in which many researchers across multiple health disciplines now work. I continue to be at the forefront of innovation in this field globally (as referred to in Achievements, research outputs and invitations that follow) and am recognised as a leader in clinical respiratory pharmacy and its management.

In 2013, I established the Quality Use of Respiratory Medicines Group (QURM Group). The QURM Groups' research in inhaler devices and respiratory medicines use more broadly has been multifaceted, both in terms of research methods, research domains (from the generation of new concepts to translation) and includes an interdisciplinary/collaboration approach.

Today, within the QURM Group works, I manage 4 programs of research (Figure 1). I have over 150 publications in high-ranked peer reviewed publications.

I have successfully awarded over \$15 M of research funding. For the following 3 years (2020-2022), I has secured over \$1M in industry grants and have applied for a further >\$2M through two NHMRC funding schemes (outcomes to be announced in 2020).

Over my academic career I has secured funding from the following organisations/schemes: Australian Research Council, Department of Health and Aging, University of Sydney, Commonwealth Govt of Australia (Guild Govt Agreement Scheme), Commonwealth Govt of Australia (Rural and Remote Pharmacy Workforce Development Program), NHMRC Co-operative Research Centre for Asthma, NHMRC Centre for Research Excellence in Severe Asthma, Asthma Foundation of NSW, Scherring Plough, TEVA Pharmaceuticals, AstraZeneca, Zentiva, Mundipharma International, MEDA Pharmaceuticals, Research in Real Life Pty (UK), University of Michigan, USA.

My research has enabled me to be a leader in the field of respiratory medicines use within the primary health care sector, having established collaborations and working relationships with a number stakeholder groups and organisations across the primary health care sector including: PHNs, the RACGP, Pharmaceutical Society, Pharmacy Guild, and a broad range of industry partners. I have outstanding working relationships across these stakeholder groups and have harnessed them to create academic output over a number of years.




Figure 1: The Quality Use of Respiratory Medicines Group

Research Income

Total research funding through international collaborations = \$8,574,449

Total grants = 10

1. **Bosnic-Anticevich S** et al., on behalf of the REG Adherence Group. Methods for measuring medication adherence and addressing adherence in asthma and COPD care. Teva Pty Ltd. Euro 70,000 (=AU\$113,800)
2. Kocks JWH, Leving MT, **Bosnic-Anticevich S**, Usmani OS, Price DB, Rodriguez MR, Tsiligianni I, Lavorini F, Dekeuijzen PNR (2020 – 2022) Real-world observational study of peak inspiratory flow rate, inhalation technique and medication adherence (PiTotal COPD Study). Novartis Pty Ltd. Euro 450,000 (=AU\$732,000)
3. Miravittles M, Usmani O, **Bosnic-Anticevich S** (2020-2022) Assessing the Utility of Peak Inspiratory Flow as. Predictor for COPD Exacerbations. Boehringer Ingelheim Pty Ltd, Euro 250,000 (=AU\$405,000).
4. Ryan D, Blakey J, **Bosnic-Anticevich S**, Buhl R, Costello R, Hellings P, Hew M, Kaplan A, Lapperre Stevens T, Price D, Roche N, Usmani O, Vrijens B. (2017) Development of a digital algorithm to predict/detect asthma exacerbations. \$130,000
5. Mares R, Khalikulov B, **Bosnic-Anticevich S**, Chrystyn H, Dekhuijzen R, Fletcher M, Papi A, Price, A, Rodriguez-Roisin (2015 – 2016). Incidence of oral thrush in COPD patients prescribed ICS as part of ICS/LABA therapy. TEVA Pharmaceuticals, \$340,000.
6. Jain A, **Bosnic-Anticevich S**, Chrystyn, H, Costello R, Dolovich M, Lavorini F, Rodriguez-Roisin, Ryan D, Price D. (2015-2016) Effectiveness of prescribing comparable vs. non-comparable devices for COPD management. TEVA Pharmaceuticals. \$380,000.
7. Khalikulov B, Ahrens R, Bjerner L, **Bosnic-Anticevich S**, Braman S, Costello R, Dekhuijzen R, Dolovich M, Fletcher M, Laube B, Lavorini F, Miravittles M, Papi A, Price D, Rand C

- (2015 – 2016) Does the cost of inhaler devices affect therapy adherence and disease outcomes? TEVA Pharmaceuticals. \$230,000
8. Price D, Chrystyn H, Lavorini F, Dekhuijzen R, Rand C, Roche N, **Bosnic-Anticevich S**. (2014-2016) ELIOT: The Easy Low Instruction Over Time (Eliot) Study. TEVA Pharmaceuticals. \$2,859,815
 9. Chrystyn H, Price D, Molimard M, Haughney J, **Bosnic-Anticevich S**, Lavorini F, Efthimiou J, Shan D, Sims E, Burden A, Hutton C, Roche N. (2014 – 2015) Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: The HI-TEC Study. ZENTIVA AUD \$482,682.
 10. Chrystyn H, van der Mole T, Ryan D, Gruffydd-Jones K, Haughney J, Roche N, Lavorini F, Papi A, Infantino A, Rodriguez M, **Bosnic-Anticevich S**, Lisspers K, Stallberg B, Henrichsen S. (2013 – 2015) Munidipharma International. The Critikaal Study. \$2,810,152

National

Total research funding = **\$8,311,389.80**

Total grants = **36**

11. **Bosnic-Anticevich S**, Cvetkovski S, Tan, R. (2020). Development and implementation of a patient-centred tool for AR management in the community pharmacy. Mylan Australia \$56,000
12. **Bosnic-Anticevich S**, Price D, Kritikos V, Katsoulotos G, Foster J, Cvetkovski B. (2020-2022) Raising the rate of referral: A novel approach to screening and referring patients at risk of severe asthma in the community pharmacy, \$377,000. GSK Pty Ltd
13. **Bosnic-Anticevich S**, Price D, Jenkins K, King G, Upham J, Hespe C, Peters M. (2020-2022) Addressing the burden of respiratory disease in General Practice: A real-life implementation study focusing on high risk asthma and COPD patients, \$600,000. GSK Pty Ltd
14. **Bosnic-Anticevich S**, Kritikos, V, Cvetkovski B, Bousquet J, Yan, K. (2019 – 2020) Improving allergic rhinitis management through the delivery of the *Allergic Rhinitis Clinical Management Pathway* educational module for community pharmacy. Mylan Australia, \$93,600.00.
15. Armour C, **Bosnic-Anticevich S**, et al., (2017 – 2019) Getting asthma under control using the skills of the community pharmacist. Commonwealth Government of Australia, Department of Health. \$2,199,100.
16. **Bosnic-Anticevich S** (2017-2018) Decreasing the burden of chronic lung diseases the community. Perpetual IMPACT Philanthropy. \$77,834.83
17. **Bosnic-Anticevich S**, Hespe C, Kritikos V, Michie B, Cvetkovski B (2018-2019). Inhaler technique mastery and maintenance in general medical practitioners: Easy Low Instruction Over Time (Dr ELIOT). TEVA Pharmaceuticals, ISS Program. \$150,000
18. Price D and **Bosnic-Anticevich S**. (2017) Clinical Audit and Educational Program for Allergic Rhinitis in Primary Care. MEDA Pharmaceuticals, \$201,050.00
19. **Bosnic-Anticevich S**, Durieux A, Carney S, Harvey R, Hellings P, Christian L, Smith P, Price D (2016-2017) Determining the burden of Allergic Rhinitis through medication management in the Australian context. MEDA Pharmaceuticals, \$50,000.
20. **Bosnic-Anticevich SZ**, Kritikos V, Cvetkovski B, Price D, Bousquet J, Yan K. (2016 – 2017) Identifying and addressing the needs of people with allergic rhinitis in primary care in Australia (Seed Funding) MEDA Pharmaceuticals, \$20,000.
21. Smith P, **Bosnic-Anticevich S**, Durieux A, Carney S, Harvey R, Hellings P, Christian L. (2016 – 2017) The burden of rhinitis in Australia. MEDA Pharmaceuticals. \$63,500.

22. **Bosnic-Anticevich S** and King G. (2016) Severe asthma: identifying patterns of medication taking behavior in primary care Centre of Excellence in Severe Asthma Seed Grant. \$20,000.
23. Asthma Research Award (2015) Bosnic-Anticevich S, National Asthma Council, \$1,000.
24. Patel M, Elaro A, **Bosnic-Anticevich S** (2015) Exploring Global Perspectives on the Management of Pediatric Asthma in the Community Pharmacy Setting, Fund for Asthma and Allergy Research, Center for Managing Chronic Disease, University of Michigan USA \$12,950.
25. **Bosnic-Anticevich S** and Price D (2014-2015) Health Care Professional: Easy Low Instruction over time (HCP ELIOT). Research in Real Life \$250,000.
26. Armour C, Benrimoj C, Saini B and **Bosnic-Anticevich S** (2014-2015) Pharmacy Asthma Study, AstraZeneca Pty Ltd, \$175,200.
27. **Bosnic-Anticevich S** and Yan K (2012-2013) iHARP asthma control study. Research in Real Life \$58,000.
28. Smith L, Ryan G, **Bosnic-Anticevich S**, McKenzie H, Ronaldson S, Bundy A. (2010) Healthcare students and patient self-management in chronic illness: A cross-faculty approach to learning practice Teaching Improvement Projects Scheme, University of Sydney \$48,909.00.
29. **Bosnic-Anticevich SZ**. University of Sydney, Thompson Research Fellowship. (2009/2010) \$60,000
30. **Bosnic-Anticevich, SZ**, Armour CL, Smith L, Saini B, Krass I, Reddel, HK. (2009) Interprofessional Learning Demonstration Project: A novel approach to self-management of chronic disease. ITA – 289/0708. Department of Health and Aging, The Commonwealth Government, \$358,267.
31. Armour CL, Saini B, **Bosnic-Anticevich SZ**, Krass I, Smith L, Stewart K, Emmerton L, Burton D. (2008) Pharmacy Asthma Care Program. Commonwealth Govt Grant as part of the Third Guild Government Agreement. \$1,400,000
32. Jenkins CR, Douglas J, Goeman, Cousens N, **Bosnic-Anticevich SZ**. (2008) Understanding the needs of older people with asthma. CRC for Asthma. \$50,000.
33. Reddel H, Sawyer S, Rand C, **Bosnic-Anticevich SZ**. (2008) Development of a simple tool to identify attitudes and beliefs associated with poor adherence with asthma medications. Asthma Foundation of NSW. \$50,000.
34. Saini B, Shah S, **Bosnic-Anticevich SZ**, Fisher M, Armour C. (2008) An Inter-professional Learning and Teaching Experience in Health Education and Prevention. The University of Sydney Teaching Improvement and Equipment Scheme, \$47,387.
35. **Bosnic-Anticevich SZ**, Armour C, Williamson M, Mackson J, Stuart M. (2008) Improving asthma device use: Innovative models for inter-professional practice. Australian Research Council. \$423,000.
36. Reddel, HK, **Bosnic-Anticevich SZ**, Correl P, Toelle B, Jenkins C, Marks. (2007) Identifying the needs of people with asthma in NSW, Asthma Foundation of NSW. \$40,000
37. Saini B, Smith L, **Bosnic-Anticevich S**, Krass I, Armour C, Shah S. (2007) Development of an educational video on asthma medications for the AAA project. Commonwealth Department of Health and Aging. \$16,000.
38. Saini B, Armour C, Krass I, Smith L, **Bosnic-Anticevich SZ**, Shah S. (2006) Interprofessional learning between medicine, nursing and pharmacy students using an evidence based peer led asthma education program. Faculty of Pharmacy, University of Sydney. 2006 (\$3000).

39. Smith L, Saini B, **Bosnic-Anticevich SZ**, Armour. (2005) Scherring Plough. Claramax and allergic rhinitis self-management. \$24,000
40. **Bosnic-Anticevich SZ**, Armour CL, Krass I and the Women for Pharmacy Group. (2005) "Women in pharmacy leadership program" commissioned to the Women for Pharmacy Committee, Pharmacy Guild of Australia, Third Community Pharmacy Guild-Government Agreement. \$165,000.
41. Smith L, Aslani P, Bajorek B, **Bosnic-Anticevich SZ**, Chen T, Krass I, Saini B, Sainsbury E.(2005) Enhancing curriculum development through the measurement of student's approach to learning. TIES, University of Sydney \$15,000.
42. Armour CL, Saini B, **Bosnic-Anticevich SZ**, Krass I, Smith L, Stewart K, Emmerton L, Burton D, Simpson M, Lough S. (2004) Pharmacy Asthma Care Program (PACP). Commonwealth Government Grant as part of the Third Guild Government Agreement. \$745,710.47.
43. **Bosnic-Anticevich SZ**, Smith L, Saini B, Krass I, Armour CL.(2004) Asthma self-management in the community – pharmacists facilitating empowerment of patient self-management practices through collaboration. Commonwealth Government Grant as part of the Third Guild Government Agreement. \$195,028.35.
44. Saini B, Armour CL, **Bosnic-Anticevich SZ**, Krass I, Taylor SJ, Dalton A, Hulme F (2003) Community pharmacy models for asthma management in rural Australia. Rural and Remote Infrastructure Grants Scheme – Rural and Remote Pharmacy Workforce Development Program. \$162,905.
45. Saini B, **Bosnic-Anticevich SZ**, Dalton A, Shah S, Taylor S, Krass I, Armour C. (2001) Managing asthma in rural communities. Asthma Innovative Management Grant Program, Department of Health and Aged Care \$60,000.
46. **Bosnic-Anticevich SZ**, Krass I, Saini B, Armour. (2000) Pharmacy Asthma Action Plan Program: Pharmacists addressing the issues in the community. Commonwealth Government Grant as part of the Third Guild Government Agreement. \$91,949.

Significant achievements

1. Establishing a secure stream of philanthropic funding for Woolcock Institute of Medical Research

In 2012, the Woolcock Institute of Medical Research, despite an outstanding national and international reputation in respiratory and sleep research, had minimal income from philanthropy (<\$12,000). In 2013, I took on the role of Director of Development to change this. In 2018, evaluation of my contribution to the Woolcock's philanthropic income indicated a 10 fold increase in annual giving and >\$5 million in major donations which have enabled the purchase of 2 major research centres in the Centre for Lung Cancer Research and the Woolcock Emphysema Centre, research scholarships and new state of the art equipment.

2. Changing the face of medicines use in respiratory management.

In 2007, my team, under my leadership was the first to publish an association between inhaler technique and clinical outcomes in asthma. Up until that time, there had been many reports of incorrect use, some literature on different methods of education however no evidence that inhaler technique actually mattered and that if inhaler technique specifically was addressed, improvements in asthma control that were equivalent to double the dose medication could be achieved. This new knowledge changed the landscape of inhaler technique research, with the emergence of more research in the area and the establishment of researchers around the world focusing on inhaler technique as a specific field of research. In 2010 I was the first to comprehensively show that inhaler technique is a skill that people can learn, but 50% do not maintain and in 2011, we were the first to suggest that inhaler technique was more than just a skill and the physical factors impacted on patients ability/willingness to use their inhalers correctly.

The impact of my leadership in this field of research and practice has changed the landscape of respiratory medicines use. This is evidenced in a number of areas but most strikingly in international guidelines for respiratory care ie. the Global Initiative for Asthma Report (GINA) and the Global Strategy for the Diagnosis, Management and Prevention of COPD Report (GOLD). Prior to 2010, inhaler technique was cited 3 times and pharmacists were not mentioned in these guidelines. In the latest updates to GINA and GOLD, inhaler technique is cited over 70 times and the role of the pharmacist highlighted 8 times. As a result of my research and leadership in this field, is now accepted that good inhaler technique is critical to good respiratory disease management, not only in terms of improved clinical outcomes, but for improved patient-related outcomes and decrease burden of disease.

My group and I continue to lead the field in clinical research around the clinical role of community pharmacy in the management of respiratory medications and disease.

3. Placing Pharmacy and Australia on the global stage of chronic upper airways disease management and respiratory medicines use research

Throughout my academic endeavours, it has become clear that within the medical and health domains, pharmacy, is generally, not considered the force in health care that we know it should be or that it certainly could be. While the scenario is different for clinical pharmacist within the hospital setting, to the broader health community and the public, pharmacy is far to commonly consider a health care business and often falls outside the multidisciplinary health care team. My team (the Quality Use of Respiratory Medicines team) has traditionally focussed on inhaler device use however over the last 5 years, we have extended our scope to include medicines for the treatment of allergic rhinitis. This is primary driven by re-surfaced trend, which acknowledges the upper and lower airways as united airways and the evidence that, a majority of patients with allergic rhinitis (and asthma) self medicate their allergic rhinitis without medical consultations and sub optimally, having significant implications on their asthma control.

Through my engagement with ARIA (Allergic Rhinitis in Asthma) I have been able to integrate the Australian perspectives into the latest ARIA Guidelines (refer to publication list) and in two

position papers on integrated care pathways and the use of apps in managing allergic rhinitis refer to publication list).

Since taking on the appointment of Chair of Pharmacy ARIA and Chair of ARIA Australia, I have been able to ensure that new evidence-based guidelines for the management of allergic rhinitis in pharmacy are development (expected to be available in late 2018) and Australian data is included in global research initiatives i.e. Australia is now officially one of the 20 countries involved in the dissemination of the MASK Mobile App (a diary for allergic rhinitis and asthma) a core global research project aiming to collect real-life data on the management of allergic rhinitis in the community (protocol published and reference #9 in publication list).

4. Establishing a primary care database in Australia (Optimum Patient Care-Australia)

Over the last 5-10 years, there has been a global trend towards two game-changing approaches to research and knowledge generation: i) Pragmatic real-life research and ii) Big data research.

Australia has followed this trend and there are several non-government and government organisations within the health domain collecting data from Australian primary care systems. Currently the two major players in this field in Australia are, NPSMedicineWise and researchers form the GRHANITE Health Information Unit, Health and Biomedical Informational Centre, University of Melbourne, who have expertise in data extraction systems. Therefore, this is an enormous amount of primary care data locked up within these systems with at least one major problem: this data is not freely available to researchers to answer important questions and there is no foreseeable mechanism by which this data would become available to researcher in the near or distant future, without financial investment.

Optimum Patient Care (OPC) is a model for practice and research based in the UK, which provides i) support to GPs to improve care delivery, ii) a mechanism for translating new knowledge into practice and iii) enables large-scale research in primary care through the establishment of an anonymised patient database. The data within the OPC UK database (currently >2 million patients) is freely available to researchers on academic request and application of a protocol, which is independently assessed by a integrity committee. I have actively been involved in collecting data for OPC UK and my research team has accessed OPC data to answer questions about the use of respiratory medicines in primary care. To date, over 100 research publications have been generated from OPC UK over the last 3 years.

In 2016, in collaboration with OPC UK, I helped to facilitate a collaboration towards the establishment of a primary care database in Australia, to be used for research, teaching and practice improvement in primary care.

To date, I have secured over \$600,000 of funding through industry partnership and philanthropic foundations, established a network of over 20 GP practice across 3 states. Currently our primary care database include the data for over 100,000 patients. This concept is the focus of my current NHMRC Partnership Application (submitted Dec 2019m valued at >\$2M) which include the following partners: OPC Australia, National Asthma Council, Lung Foundation Australia, Royal Australian College of General Practice, 4 x Primary Health Networks in 4 states including metropolitan and rural locations).

As this initiative continues to grow, it will provide a unique opportunity for researchers in pharmacy, medicine and health to develop and engage in translational research, both within Australian and internationally.

5. Advancing the passage for women in pharmacy

In 2002 I co-founded the Women for Pharmacy Committee and serviced as its Chair for 5 years. The Women for Pharmacy Committee comprised of 10 members, made up of registered pharmacists across the spectrum of the profession, including practicing pharmacists in community and hospital, pharmacists in industry and academia, pharmacists in professional organisations. Their mission was to support women in pharmacy to achieve their career aspirations through the establishment of professional networks. This resulted in the establishment of 8 women's networks

in Tasmania, Victoria, Queensland, South Australia, Western Australia, the Australian Capital Territory and two rural NSW centres (Wagga Wagga and the Blue Mountains). From these networks hundreds of women in pharmacy have benefited, successfully attaining employment, establishing business partnerships and successfully achieving selection onto professional pharmacy organisation boards, including the Pharmacy Guild of Australia and The Pharmaceutical Society of Australia. After 2009, the Women for Pharmacy Committee was integrated into the Women and Young Pharmacists committee (Pharmacy Guild of Australia).

6. Mentoring legacy

I have an extensive history of mentoring, having supervised 12 PhD students (9 while holding a 0.6FTE) and >50 MPhil, Honours research students as primary supervisor (82% females). I have mentored several early career research to successful positions and impact in their fields of research and in the community. Following is a list of selected past PhD students and their currently roles. This does not include other mentoring, listed elsewhere.

- Professor Iman Basheti, Dean of Pharmacy at the University of Aman
- Dr Lynn Cheong, Clinical Assistant Professor, Pharmacy School, Canberra University.
- Dr Cherie Tsingos, Lecturer in Pharmacy Practice, University of Technology, Sydney.
- Dr Sharon Davis, Associate Lecturer in Pharmacy Practice, University of Sydney.
- Dr Cassandra Slader, Senior Global Management with Novartis Pty Ltd
- Dr Amanda Elaro, Senior Medical Scientific Liaison, GSK Pty Ltd.
- Dr Vicky Kritikos, Research Fellow at the Woolcock Institute of Medical Research and Specialist Asthma Pharmacist (The Asthma Centre)
- Dr Ludmila Ovchinnikova, Senior Research Administrator at the Garvan Institute of Medical Research

Since 2010, I have mentored over 10 ECRs for the Sydney Medical School's ECR program, across multiple disciplines and continue to provide mentorship as they progress to funding success and promotion.

I have had 100% responsibility in established 3 mentoring programs:

1. The Business Undergraduate Mentoring Program (2007); an innovative program, first in Australia, connecting pharmacy students to entrepreneurs.
2. The Faculty of Pharmacy Mentoring Program (2008); the first formal mentoring program for Levels A-C academics in pharmacy (USyd).
3. The Women for Pharmacy Committee (Chair until 2009) whose mission it was to mentor female pharmacists working in research, practice and/or industry, to achieve their career aspirations. Detailed above.

4. Curriculum development

While I have developed and implemented several courses within the pharmacy curriculum, there are two in particular that were Australian firsts: Pharmacotherapeutics (A and B) and BUMP (Business Undergraduate Mentoring Program). I was instrumental in the conceptualisation, development and implementation of these courses. Both of these courses were introduced into the undergraduate Bachelor of Pharmacy curriculum and were the first of their kind in Australia.

Pharmacotherapeutics (A and B) (2000)	This course was the first problem-based learning course in a Pharmacy undergraduate curriculum in Australia. It was based on the Clinical Reasoning Process used in medical education and it was designed to integrate with a Clinical Practice Unit of Sydney. The course was delivered in small-group tutorials, in which tutors facilitated the learning process rather than the content. Following the introduction of this course, I was invited to assist with the development of similar courses in other pharmacy schools in Australia.
---------------------------------------	---

BUMP
(2007)

Through her engagement with and support from the Pharmacy Practice Foundation (refer to Service portfolio for details), I was given the opportunity to develop a program of mentoring for undergraduate students in which entrepreneurial pharmacists in the area of business and management, mentoring undergraduate pharmacy students over a 12 month period. In the development of BUMP which was a 12-month program consisting of workshops and practice-based experience, students enrolled in the program were partnered with an entrepreneurial pharmacists. I worked in consultation with entrepreneurial pharmacists and accountants in the area of pharmacy to develop this program.

This was a novel and innovative program and the only one of its kind in an Australian pharmacy school.

Feedback from students was outstanding and in addition to the experience and knowledge gained by students, the program was an integral part of relationship development between the Faculty of Pharmacy and the profession of pharmacy. The impact of the Global Financial Crisis resulted in funding no longer being available after 3 years.

The impact of this course on students and the Faculty of Pharmacy's leadership in the area of pharmacy and business was significant with students from the Faculty of Pharmacy, University of Sydney winning the inaugural National Students Business Plan Competition (Pharmacy Guild of Australia),

5. Interprofessional relationships, education and practice

I have extensive experience in developing education, educational interventions and curriculum across the health disciplines, including medicine and nursing. Over the last 5 years, I have developed workshops and continuing professional modules and delivered them to over 5000 registered medical health care professionals. I have received 2 major grants in interprofessional education and have 3 publications specifically in interprofessional education. I have also been successful in attracting funding specifically for interprofessional research within the respiratory field of research.

Interprofessional Grants:

1. **Bosnic-Anticevich, SZ**, Armour CL, Smith L, Saini B, Krass I, Reddel, HK. (2009) Interprofessional Learning Demonstration Project: A novel approach to self-management of chronic disease. ITA – 289/0708. Department of Health and Aging, The Commonwealth Government, \$358,267.
2. **Bosnic-Anticevich SZ**, Armour C, Williamson M, Mackson J, Stuart M. (2008) Improving asthma device use: Innovative models for inter-professional practice. Australian Research Council. \$423,000.
3. **Bosnic-Anticevich, SZ**, Armour CL, Smith L, Saini B, Krass I, Reddel, HK. (2009) Interprofessional Learning Demonstration Project: A novel approach to self-management of chronic disease. ITA – 289/0708. Department of Health and Aging, The Commonwealth Government, \$358,267.

Interprofessional Publications

Bosnic-Anticevich S, Callan C, Chrystyn H, Lavorini F, Nikolaou V, Kritikos V, Bekhuijzen PNR, Roche N, Bjermer L, Rand C, Zwar N, Price DB. Inhaler technique mastery and maintenance in healthcare professionals trained on different devices. *Journal of Asthma* (Accepted March 2017).
Bosnic-Anticevich, SZ, Stuart M, Cvetkovski B, Sainsbury E, Armour C, Mavritsakis S, Mendrela G, Travers-Mason G, Williamson M. (2014) Development and evaluation of an innovative model of inter-professional education focused on asthma medication use. *BMC Medical Education* 14:72, <http://www.biomedcentral.com/1472-6920/14/72>.

Saini B, Shah S, Kearey P, **Bosnic-Anticevich S**, Grootjans J, Armour C. (2011) An interprofessional learning module on asthma health promotion. *American Journal of Pharmaceutical Education* 83(3): 295-302.

I continue to work in within multidisciplinary research teams and continues to be the go-to research in the field of respiratory medicines use amongst her interprofessional peers.

Professional Leadership and Policy

My leadership across policy and professional fields has focused on activities that facilitate the generation of real-world evidence and enhance its translation into practice, in particular with a primary care focus. Recent significant highlights include:

1. INAUGURAL CHAIR (2016-current) of the international scientific committee responsible for the development of Allergic Rhinitis In Asthma (ARIA) Management guidelines for pharmacists and member of the scientific committee (2015 – current) for overarching ARIA guidelines.
2. DIRECTOR AND PRESIDENT-ELECT OF THE RESPIRATORY EFFECTIVENESS GROUP (REG) (2016-current), an independent global, investigator-led, research initiative of > 300 researchers (40 countries) that focuses on harnessing real-life evidence to inform policy. I have worked hard to broaden the network of global investigators to now include researcher from multidisciplinary backgrounds across Asia and the Pacific region.
3. FIRST PHARMACIST TO BE CO-CHAIR OF THE PRIMARY CARE SPECIAL INTEREST GROUP (SIG) of the Thoracic Society of Australia and New Zealand (TSANZ) (2017-current). In this role I am bridging the gap between practising primary care Health Care Professionals and the scientific respiratory community in Australian and NZ. To date, we have seen a doubling of the number of primary care SIG abstracts submitted for presentation to the 2020 TSANZ Scientific Conference.
4. ONLY INVITED PHARMACIST to sit on scientific international Advisory Boards on inhaler devices for the pharmaceutical industry including Teva, Boehringer Ingelheim, AstraZeneca, GSK, Sanofi providing strategic input into future research directions.
5. ASSOCIATE EDITOR of several multidisciplinary high impact journals: European Respiratory Society Monograph, European Respiratory Review and a regular reviewer for 26 local and international journals (20-30 reviews/year)
6. EXPERT REVIEWER of 10 inter/national granting bodies (2-5/year) including MRFF Primary Care (accepted invitation for April 2020), Asthma Australia, Health Research Council of NZ, Asthma UK, Health Research Board (Ireland), Euro Regional Develop Fund (EU).

Management and/or other professional experience

2013 – ongoing Research Leader of the Quality Use of Respiratory Medicines Group, Woolcock Institute of Medical Research

I currently lead, mentor and manages a research team of >10 researchers. In 2013 I introduced a 'team structure' within her group in recognition of critical mass established and the emerging sub-speciality areas in which the group was working. I have employed a clinical advisor/lead, who is also a mid-career researcher to help mentor junior staff and ensure that all the groups research is grounded in current and emerging clinical problems and maintains translational value. My group's ethos is one of integrity, trust, and respect, in which each team member is valued, appreciated, supported and enabled to achieve their full potential.

2018 – ongoing Co-Chair of the Primary Care Special Interest Group of the Thoracic Society of Australia and New Zealand

Along with her Co-Chair, I am responsible for the leadership of this SIG within Australia's national thoracic society. In this role she is currently aiming to better integrate primary care practitioners into the TSANZ.

2016 – ongoing, Chair of Pharmacy Allergic Rhinitis and its Impact on Asthma (Pharmacy ARIA)

ARIA (Allergic Rhinitis and its Impact on Asthma) is a non-governmental organization (NGO) working in collaboration with the World Health Organization. The purpose and mission of ARIA is to educate and implement evidence-based management of allergic rhinitis in conjunction with asthma, worldwide through:

- planning, managing, and financing pilot projects to improve the health of broad sectors of the population throughout the world
- setting up rural healthcare activities
- providing support for preventive, diagnostic, and therapeutic measures as part of basic healthcare.

ARIA is a member of the Global Alliance Against Chronic Respiratory Disease (GARD), a WHO-organised project.

As Chair of Pharmacy ARIA, I am responsible for providing academic leadership in matters related to pharmacy and allergic rhinitis. The purpose of this role is to ensure that the views, perspectives and interests of pharmacists as health care providers is incorporated into all initiatives/guidelines/reports issued and promoted by the ARIA initiative. In this role I am required to work with a broad range of stakeholders ranging from practising health care providers (HCPs), researchers and the industry. Over the last 12 months I have been working with pharmacists to generate evidence (where appropriate) and perspectives on matters related to the management of allergic rhinitis in the community. Based on these findings, new ARIA guidelines for pharmacy are currently in press.

2017 – ongoing, Chair of ARIA Australia

As Chair of ARIA Australia, my role is to enable the translation of ARIA guidelines more broadly into practice in Australia. For example, latest recommendations from ARIA suggest the use of an allergic rhinitis App to help monitor and treat allergic rhinitis. Working with collaborators, she has been able to implement ARIA recommendations into continuing professional education for HCPs. Further to this, I am working with allergy researchers, industry and ASCIA (Australasian Society of Clinical Immunology and Asthma) to develop initiatives and opportunities to promote the implementation of the latest guidelines and use of new technologies for the management of allergic rhinitis. Currently she is working with the ASCIA and the National Asthma Council on two initiatives for 2017.

2016 – ongoing, Executive Committee /Director of the Respiratory Effectiveness Group (REG).

REG is a global, investigator-led, not-for-profit research initiative that has been set up in recognition of the potential value of real-life research and the need to harness real-life evidence to inform meaningful practice guidelines, drug licensing and prescribing decisions. There are over 300 international researchers who are REG collaborators from over 40 countries. REG currently hosts 14 working groups across the different areas of respiratory research.

REG aims to harness the growing momentum in real-life respiratory research and includes:

- Providing leadership and contributing to the development of setting research standards
- Evaluating mechanisms for integrating real-life research appropriately into clinical practice guidelines
- Evaluating how real-life research findings can be appropriately incorporated into clinical practice
- Providing ethical review and registration of real-life research study protocols
- Communicating best practice standards in real-life research
- Work collaboratively with organisations (guideline bodies, research organisations and beyond) committed to the shared-goals of the group.

I am one of 5 members, the only pharmacist and the only female, on the Executive Committee/Director of REG, having an academic leadership role. Achieving selection on the Executive Committee was through an internationally competitive process, hence it is highly sought after and influential role. I am one of two researchers responsible for overseeing research within the organisation. This role covers all aspects of research within REG including examining and

prioritising research needs within REG, addressing key issues and requirements for high-quality evidence and standards and providing a clear focus for the future research initiatives to be conducted by REG.

2014 – onwards, Academic partner of Optimum Patient Care- Australia (OPC Australia)

On behalf of the Woolcock Institute, I serve as the primary academic lead of Optimum Patient Care in Australia (OPC Australia). OPC Australia is based on the OPC UK i.e. a model for practice and research, which provides i) support to GPs to improve care delivery, ii) a mechanism for translating new knowledge into practice and iii) enables large-scale research in primary care through the establishment of an anonymised patient database. This database follows patients longitudinally enabling important research questions to be answered in primary care. Since 2016 I have been working with researchers, Central and Eastern Sydney PHN, the Sydney Local Health District to establish OPC-Australia. This role involves high level management skills and relationships with local and international stakeholders, the generation of novel research ideas and the sourcing of funding.

2016 University Local Promotion Committee for Level C to Level D Appointments

2010 – ongoing Academic Board Nominee

2008-ongoing, 'Early Career Researcher' Mentor

As noted above.

2011 – 2014 Thoracic Society of Australia and New Zealand (TSANZ) Research Subcommittee

This is a highly prestigious position within the respiratory discipline in Australia. I was the first and only pharmacy researcher to sit on this committee.

2007 – 2010 Health Data Linkage (HDL) Committee

I served as the Faculty of Pharmacy representative on the HDL Committee for 3 years. Her role was to promote the role of data linkage within the University and to evaluate submissions for data linkage access submitted to the committee from researchers within the University.

2006 – 2008 Faculty of Pharmacy Research and Innovation Committee (formally the Faculty of Pharmacy Research Committee)

I was the pharmacy practice representative on the Faculty of Pharmacy Research and Innovation Committee (formally the Faculty of Pharmacy Research Committee). During this time she developed the Faculty of Pharmacy Mentoring Program (mentioned previously), which was developed as a formal mentoring program for academics within the Faculty of Pharmacy from Levels A-C. The implementation of this program in 2009 became the responsibility of the Research and Innovation Committee as I commenced her Thompson Fellowship in 2009.

2006 – 2008 Pharmacy Practice Foundation Executive Committee

I was the Faculty of Pharmacy staff representative on the Pharmacy Practice Foundation Executive Committee. As part of this role, she worked with the Pharmacy Practice Foundation Executive Committee in fundraising activities mostly associated with gaining sponsorship from the pharmaceutical industry. In particular, I was actively involved in discussions with industry, which resulted in the establishment of first Asthma Specialist Pharmacist position in Australia. This position was significant as it incorporated a pharmacist within an asthma multidisciplinary team for the first time. This role also involved teaching undergraduate pharmacy students as part of the B.Pharm degree about the possibilities for extended practice in respiratory medicine.

2005 – 2012 Secretary, Australia Pharmaceutical Sciences Association (APSA)

I was responsible for the general running of the APSA Executive Committee.

2005 College of Health Sciences “postgraduate research best practice” working party

As a working party member I was involved in the identification of core and optimal components of postgraduate studies across the then College of Health Sciences.

2004-2009 Pharmacy Practice Senior Management Team, Faculty of Pharmacy

This was an executive team of pharmacy practice staff. From 2003 – 2004 I was responsible for matters related to pharmacy practice staff including the management of 13 Practitioner Teachers and other staff development issues. From 2005 onwards I also held responsibility for the Research Portfolio of the discipline of pharmacy practice, which involved promotion, coordination and seeking funding opportunities.

2004 Postgraduate committee at the Faculty of Pharmacy Academic Accreditation review

Member of the Dean’s Advisory Committee representation for the Faculty of Pharmacy during the New Zealand and Australian Pharmacy Schools Accreditation Committee Review. In this role I was required to report on all issues associated with postgraduate research to the Accreditation Board.

2003 International Pharmacy Federation (FIP) Conference Students Day Organising Subcommittee

Sole member responsible for organising the Students day at which Pharmaceutical Industry representatives spoke to students about the various careers for pharmacists in the pharmaceutical industry.

2002 – 2009 Founder and Chair, Women for Pharmacy Committee

As described above.

2001-2006 Deputy Chair of the Post-graduate Studies Committee and then Postgraduate Research Committee

In this role I was responsible for the development and implementation of the Faculty of Pharmacy Postgraduate Progression Guide, for the co-ordination and development of the Post Graduate Annual Interviews (including the development of the interview guides used to guide interviews (pre-online Annual Postgraduate Progress Reporting) and conducting interviews).

I was responsible for recruitment of honours students through the Pharmacy Research Day, usually held late in Semester 2. This research day was designed to attract Year 3 undergraduate students to an afternoon of poster and oral research presentations at which potential honours students could meet with researchers within the Faculty. Commonly this activity attracted over 100 Year 3 pharmacy undergraduate students. It was following the Pharmacy Research Day that students were required to lodge their interest in enrolling in the honours program for the subsequent year.

2001 – 2002 International Social Pharmacy Network Meeting Organising Committee

I was the Committee fundraiser responsible for obtaining sponsorship from the Pharmaceutical and Pharmacy Industry (\$39,000).

2001 – 2004 New Staff Members Committee, Faculty of Pharmacy

In this role, I was responsible for the development of guidelines for new academic staff commencing employment within the Faculty of Pharmacy.

2000 – 2003 Chair of the Masters of Pharmaceutical Industry Committee, Faculty of Pharmacy

In this role I was instrumental in the development of the course outline and submission for a Masters of Pharmaceutical Industry to the Academic Board of the university. This role involved

liaising between the university and stakeholders from the Pharmaceutical Industry during development of the course proposal.

2000 – 2002 Pharmacy Practice Foundation Specialists Practitioner Teachers Committee

I was the pharmacy academic representative on this committee and my role was to provide academic input into fundraising activities associated with the establishment of a teacher practitioner positions. Specifically, she was directly involved in securing funding for the diabetes specialist practitioner teacher.

Student supervision

Please note: in all cases “Supervisor” denotes ‘primary supervisor’.

Name of student	Title	Completion date	Role
-----------------	-------	-----------------	------

Current Students

1. Joseph Doan	Optimizing the delivery of respiratory care in general practice	PhD, 2023	Supervisor
2. Mariam Toumas	Exploring novel interventions For inhaler device training	PhD, 2022	Supervisor
3. Sarah Barbara	The use of inhalers by elderly patients	PhD, 2022	Supervisor

Completed Students

Doctor of Philosophy

4. Pamela Srour	Autonomy in inhaler device use of pediatric patients with asthma: a parent/guardians' perspective	2019	Supervisor
5. Elizabeth Azzi	Understanding the relationship between Inhaler technique and adherence	2019	Supervisor
6. Biljana Cvetkovski	Understanding AR in the primary care	2019	Supervisor
7. Cherie Tsingos	Self-director learning.	2016	Associate Supervisor
8. Rachel Tan	Allergic rhinitis management in the community pharmacy	2019	Supervisor
9. Amanda Elaro	PACE in Pharmacy	2016	Supervisor
10. Sharon Davis	Understanding the Inhaler Device Needs of People with Intellectual Disabilities	2015	Supervisor
11. Lynn Cheung	The role of the patient in Inter-professional care	2014	Supervisor
12. Ludmila Ovchivnikova	Understanding the reasons for poor inhaler technique	2013	Supervisor
13. Cassandra Slader	Complimentary and Alternative medicine for asthma	2006	Supervisor
14. Vicky Kritikos	Innovative Asthma management by Community Pharmacists in Australia	2007	Supervisor
15. Iman Basheti	The impact of correcting Inhaler technique: Improved Asthma outcomes with a Simple intervention by Community pharmacists	2007	Supervisor

Master of Philosophy

16. Samantha Khuu	Medication Profiling of patients with complex asthma in the community	2017	Supervisor
17. Sofia Mavritsakis	Sociocultural Theory and Interprofessional Relationships	2013	Supervisor

18. Lia Jahedi	Patient preference for inhaler devices and impact on inhaler technique.	2014	Supervisor
19. Biljana Cvetkovski	Asthma Management in Rural NSW: Perceptions of health care professionals and people with asthma	2008	Supervisor
20. Rosalind Dey	Professional Relationships	2008	Supervisor

Master of Pharmacy

21. Joep Jacobs (University of Utericht, Netherlands)	Sustainability of clinical and humanistic benefits achieved as a result of specialized Community pharmacy care Model.	2008	Co-Supervisor
22. Ameerul Hussein	Patient Satisfaction of a Community Based Opioid Substitution Program in a low Socio-economic area of NSW	2007	Supervisor
23. Patrick Van	Comparison of Nebulised vs MDI-spacer delivered beta2 Agonist therapy in patients with asthma in the community	2003	Associate Supervisor
24. Stephen So	Information Seeking Behaviour of people with Asthma investigating Patient needs and addressing them.	2003	Supervisor
25. Vicky Kritikos	Pharmacy Students' Perceptions Of their profession relative to other health care professionals	2003	Supervisor

Bachelor of Pharmacy (Honours)/Bachelor of Science (Honours)/ Graduate Diploma of Pharmaceutical Sciences

26. Thomas Bradbury	Predicting asthma outcomes from medication dispensing patterns	Honours, 2018	Supervisor
27. Rachel Tan	AR management in practice: understanding what patients actually do.	2015	Supervisor
28. Luca Pomare	Collaboration between GPs and pharmacists around Childhood asthma	2012	Supervisor
29. Louis Cheung	Understanding GP perspectives on collaboration in primary care	2009	Supervisor
30. Yvonne Nguyen	Do health professionals on Respiratory wards know How to use their inhalers?	2008	Supervisor

31. Mona Abdelnour	What is the role of the Pharmacist in a multidisciplinary asthma clinic	2008	Supervisor
32. Mariam Toumas	Comparison of small group Training with self directed Internet based training in inhaler technique	2007	Supervisor
33. Mona Swan	The use of inhaler devices by elderly patients with COPD.	2006	Supervisor
34. Elaine Cheung	Exploring facilitators and Barriers to pharmacy Students and graduates Undertaking research careers	2006	Supervisor
35. Sean Minh Guah	Assessing and Evaluating Patient Satisfaction with the Community Pharmacy Asthma Self Management Program	2005	Supervisor
36. Yew Kent Lok	Location, location, location: Where to patients keep Their asthma inhalers	2005	Supervisor
37. Ludmilla Ovchivnikova	Asthma self management Behaviour in the context of Self-regulation theory	2004	Supervisor
38. Catherine Murphy	Asthma and physical activity: How do they interact to Affect quality of life	2004	Supervisor
39. Hui Shen Chen	The challenge of Assessing asthma knowledge	2003	Supervisor
40. Gavan Ooi	General Practitioners Perceptions on asthma and its Management in rural NSW	2003	Supervisor
41. Sugan Pillay	General Practitioners' Perspectives on practice Guidelines in asthma management	2005	Supervisor
42. Harun Sinha	Sustainability of metered Dose inhaler technique	2002	Supervisor

43. Lucy Collis	Salbutamol sulfate CFC-free Metered dose inhalers: effects Of washing inhaler mouthpiece On aerosol performance And potential clinical Consequences.	2002	Supervisor
44. Amy Donnelly	Impact of a peer-led asthma Education program on asthma Knowledge, confidence and skills	2002	Supervisor
45. Mouna Sawan	The assessment of metered Dose inhaler Technique In patients	2002	Supervisor
46. Iman Basheti	Understanding patients Inhaler technique history	2001	Supervisor
47. Josephine Lombardo	Interprofessional views on Asthma Action Plans	2001	Supervisor
48. Stephen So	The effect on metered dose Inhaler technique of Educational interventions by Pharmacists.	2001	Supervisor
49. Biljana Kraljevska	Poor Turbuhaler Technique by Community Patients	2000	Supervisor
50. Cassandra Slader	CFC Free Metered Dose Inhalers – Do patients know What to do?	2000	Supervisor

MD Research and Pharmacology Research Elective Students

51. Grace Gillett Pharmacology Research Elective(PCOL3021)	Health networks and adolescents with asthma.	2014	Supervisor
52. Nay Htoo Aung Pharmacology Research Elective(PCOL3021)	Influence of the Media and social networks on health-seeking behavior of patients with asthma.	2014	Supervisor
53. Rachel Tan Pharmacology Research Elective(PCOL3021)	Assessing the intuitive nature of device use.	2014	Supervisor

54. Shizuka Yamauchi Pharmacology Research Elective(PCOL3021)	Improper use of ICS as a key factor leading to non-adherence to asthma medication	2014	Supervisor
55. Stacey Santoso Pharmacology Research Elective(PCOL3021)	Determine intuitiveness of device maintenance.	2014	Supervisor
56. Stephanie Yvonne Yee Pharmacology Research Elective(PCOL3021)	Device use of naïve individuals to novel inhalers.	2014	Co-Supervisor
57. David Kopinski MD	Pharmacy Student's perceptions of the PACE educational module of communication.	-2016	Supervisor
58. Rashmee Dhunnoo MD	Factors affecting Inhaler device use.	2016	Supervisor
59. Tali Feiglin MD	Understanding adherence in asthma management.	2016	Supervisor
60. Erwinpreet Kaur MD	Exploring effective interventions for improving inhaler device technique mastery and maintenance.	2016	Supervisor
61. Lynette Fahar MD	Identifying effective asthma medication adherence interventions.	2016	Supervisor
62. Zachary Smekel MD	GP's perception to Allergic Rhinitis Management	2016	Supervisor
63. Charlotte Webber MD	Asthma and patient perspectives	2020	Supervisor
64. Jack Evans MD	Inhaler use by general medical practitioners in real life	2020	Supervisor
65. Justine Yu MD	Allergic rhinitis in asthma and patient perspective on disease control	2020	Supervisor
66. Sara Alamyar MD	Decreasing the burden of asthma in the community	2020	Supervisor

List of courses developed, coordinated and taught within the University of Sydney

I have extensive experience as an educator. Her teaching portfolio consists of activities associated with the traditional academic role as well as continuing professional education to practicing pharmacist, general medical practitioners and respiratory physicians.

During my time in the Faculty of Pharmacy, she taught in 28 Units of Study, details of which are summarised in the table below. During this time I was involved in developing curricula across the length of the pharmacy curriculum. My contribution to curriculum development is indicated with an “*” in the table that follows.

Year	Unit of Study	Duties	Degree
2015	*PHAR4811	Curriculum development and delivery	Bachelor of Pharmacy
2014 -2017	MD Research Project	Student supervision	MD
2014 - 2014	Drug Therapy (PCOL3021)	Student supervision	Bachelor of Science
2014 - 2014	Neuropharmacology (PCOL3022)	Student supervision	Bachelor of Medical Science
2010 - 2012	Pharmacy Practice (PHAR2822)	Lecturers	Bachelor of Pharmacy
2011	Professional Pharmacy (PHAR4821)	Workshop leader	Bachelor of Pharmacy
2010-2011	Respiratory (PHAR3812)	Lecturers	Bachelor of Pharmacy
2008, 2010	Social Pharmacy (PHAR1821)	Tutor	Bachelor of Pharmacy
2006- 2007	*Pharmacy Practice 2 (PHAR2617)	Curriculum development, coordination and teaching	Bachelor of Pharmacy
2006 -2007	Pharmacotherapeutics in Practice (PHAR4616)	Tutor	Bachelor of Pharmacy
2007 -2011	Pharmacy Practice C (PHAR5510)	Tutor	Master of Pharmacy
2007 -2011	Pharmacy Practice C (PHAR5510)	OSCE assessor	Master of Pharmacy
2006, 2007, 2009	Pharmacy Practice 3B (PHAR3614)	OSCE assessor	Bachelor of Pharmacy
2006 - 2008	Pharmacy Practice 3A (PHAR3613)	OSCE assessor	Bachelor of Pharmacy
2005 -2012	*Pharmacy Practice 2B	Curriculum development and coordination.	Bachelor of Pharmacy
2005 -2012	*Pharmacotherapeutics in Health Care	Curriculum development and restructuring	Master of Pharmacy
2000-2004	*Pharmacotherapeutics A	Curriculum development and restructuring	Bachelor of Pharmacy
2000-2004	*Pharmacotherapeutics B	Curriculum development and restructuring	Bachelor of Pharmacy
2000-2004	Clinical trials	Lecturer and examiner	Master of Herbal Medicine
2000-2004	Respiratory Pharmacology	Lecturer	Master of Herbal Medicine
2000-2004	Social, behavioural and professional pharmacy	Teaching	Bachelor of Pharmacy
2000-2004	Pharmacy Practice 2B	Lecturer and Examiner	Bachelor of Pharmacy

2000-2004	Pharmacy Practice 2B	Lecturer	Bachelor of Pharmacy
2000-2004	Pharmacy Practice 3A	Examiner	Bachelor of Pharmacy
2000-2004	Pharmacy Practice 3B	Lecturer and Examiner	Bachelor of Pharmacy
2002-2004	Nursing and Biomedical interventions	Lecturer	Bachelor of Nursing
2005 -	*Pharmacy Practice 2B	Curriculum development, coordination and teaching	Bachelor of Pharmacy
2005 -	*Pharmacotherapeutics in Health Care	Curriculum development, coordination and teaching	Master of Pharmacy
2000-2004	*Pharmacotherapeutics A	Curriculum development, coordination and teaching	Bachelor of Pharmacy
2000-2004	*Pharmacotherapeutics B	Curriculum development, coordination and teaching	Bachelor of Pharmacy

Teaching activities developed and delivered to practising health care professionals as part of continuing professional education for registration (last update in 2017).

Year	Educational Activity	Audience	Duty
2017	Clinical review and education Program	General Practitioners (~120)	Workshops based on clinical review of patients with asthma, involving risk identification and optimisation of medication management.
2016	Inhaler devices workshop	Registered nurses, medical practitioners and pharmacists (~100)	Devices workshop delivered as part of a continuing education session at the Thoracic Society of Australia and New Zealand conference.
2016	Respiratory professional services workshop	Registered pharmacists (~150)	Interactive workshop on the delivery of respiratory services in pharmacy
2013-2017	Inhaler device and adherence lectures (Sydney x 2, Seoul, Korea x 2, Valencia, Spain, Barcelona, Spain, Guangzhou, China)	General medical Practitioners and respiratory physicians (~100/lecture; 7 in total)	Delivery of lectures on evidence-based practice and innovation in inhaler devices use.

Professional Memberships and Associations

Australian Association of Academics in Primary Care (AAAPC)
Australasian Society of Clinical Immunology and Allergy (ASCIA)
Australasian Pharmaceutical Sciences Association (APSA)
International Pharmacy Federation (FIP)
International Primary Care Respiratory Group (IPCRG)
Pharmaceutical Society of Australia (PSA)
Primary Health Care Research and Information Service (PHCRIS)
The American Thoracic Society (ATS)
The European Respiratory Society (ERS)
The European Society of Allergy and Clinical Immunology (EAACI)
The Society of Hospital Pharmacists of Australia (SHPA)
Thoracic Society of Australia and New Zealand (TSANZ)
Respiratory Effectiveness Group (REG)
Allergic Rhinitis in Asthma (ARIA)

Current contributions to professional associations only

Respiratory Effectiveness Group - Vice President and Director
Allergic Rhinitis in Asthma – Chair of ARIA in Pharmacy
Thoracic Society of Australia and New Zealand - Co-Convenor of the Primary Care SIG
European Association of Allergy and Clinical Immunology – Primary SIG Executive Committee

Review Boards

American Journal of Pharmacy Education
Australian Journal of Pharmacy
International Journal of Pharmacy Practice
International Journal of Clinical Pharmacy
Journal of Pharmacy Practice and Research
Patient Education and Counselling Pharmacy Practice
Research in Social and Administrative Pharmacy

Asia Pacific Journal of Health Promotion
BMC Pulmonary Medicine
Clinical Respiratory Journal
Drug Delivery
European Respiratory Journal
European Respiratory Review
Journal of Aerosol Medicine and
Pulmonary Journal of Allergy and Clinical
Immunology
Journal of Allergy and Clinical
Immunology: In Practice
Medical Journal of Australia
Pragmatic and Observational Research
Pulmonary Therapy
The Annals of Pharmacotherapy.
Biomedical Research International
npj Primary Care Respiratory Medicine
Biomed Research International
Clinical and Translational Allergy
Journal of Clinical Medicine
PLOS ONE
Drugs and Aging

Editorial Boards/Professional Leadership

2020 – current Frontiers in Allergy
2020 – current Pharmacy
2020 – current Medicina (IF 1.205)
2019 – current Editorial Board, ERS Monograph, a quarterly Journal of the ERJ (IF 12.2)
2018 – current Editorial Board, Pulmonary Therapy
2017 - current Associate Editor, European Respiratory Review (IF 4.29)

Grant/Application reviews

Thoracic Society of Australian and New Zealand Research Grants
Australian Lung Foundation Research Grants
NHMRC- Project Grants Scheme
NSW Asthma Foundation
Asthma Australia
Asthma UK
Concord Repatriation General Hospital Human Research Ethics Committee
Health Research Council of NZ

Invited Talks and presentations

2020

1. Symposium: Drug Delivery to the Lungs (DDL) Scientific Conference “DIGITAL Inhalers - a panacea for respiratory patients? International 9-11 Dec 2020
2. Expert session: “Connecting inhaler in the clinic: reviewing the evidence” European Respiratory Society annual congress 6-9 September 2020
3. Expert session: “Inhalation matters in COPD: Making a patient-centred choice” European Respiratory Society annual congress 6-9 September 2020
4. HealthEd Webinar. Inhaler Devices in clinical practice. Australia May 2020
5. Respiratory Symposium. Putting Patients at the Centre of Care. Korea, July 2020
6. Respiratory Summit: Inhalation therapy: personalized selection of inhaler devices. Tiachung, Taiwan, June 2020
7. Respiratory Symposium: Acute Respiratory Care: Time of Change Symposium. Virtual, Australia June 2020
8. Respiratory Summit: Inhalation Matters: the importance of inhaler choice in COPD, Australia, April 2020

2019

9. COMPASS webinar– A path to better outcomes in COPD. Webinar to Community Pharmacists, Boehringer Ingelheim, Australia July 2019
10. Symposium: Putting COPD patient needs first: time for optimising treatment and device selection. Asia Pacific Respiratory Society Congress, Hanoi Vietnam.
11. Symposium: Critical Errors: what matters in inhalation technique, Respiratory Forum Asia, China, May 2019
12. Symposium: The choice of inhaler device: Influence on treatment success, Respiratory Forum Central America, Mexico City, January 2019
13. Symposium: Inhaler technique in practice: what really matters and why. Inhalation Asia, Hong Kong 2019
14. Symposium: Continued innovation in respiratory care: Current concepts in inhaler devices. Heart and Lungs National GP Symposium, Sydney, May 2019
15. Invited Talk: Electronic monitoring and inhaler technique: Overcoming the challenge of inhaler technique and poor adherence: The raising awareness of adherence, European Respiratory Society Congress, Madrid 2019.

2018

16. Plenary Continued innovation in respiratory care: Current concepts in inhaler devices, Heart and Lungs Symposium, Melbourne, October 2018.
17. Oral Symposium: Take a breathe: Is inhaler technique really so complex? European Respiratory Society Annual Congress, Paris, France, September 2018.
18. Oral Symposium Presentation: Getting it right: How we can help out patients manage their inhalers. European Respiratory Society Congress, September, Paris, France. 2018.

19. Symposium Presentation: *State-of-the-Art Methods for Teaching Inhaler Technique* ', International Conference on Communication in Healthcare, Porto, Portugal 4 September 2018.
20. Symposium Presentation: *Critical Errors and their role in optimizing respiratory medication use*: Asia Respiratory Symposium, Cebu, Philippines. June, 2018.
21. Symposium Presentation: *Continued innovation in respiratory care: The importance of inhaler devices*: European Respiratory Symposium, Vienna. April, 2018.
22. Webinar: *History and Innovation in Inhalation Techniques in asthma and COPD*, Respiratory Knowledge Academy Update, Abu Dhabi, United Arab Emirates, March 2018.

2017

23. Oral Symposium Presentation: *An informed and motivated health care team*. Primary Care Symposium, European Respiratory Society Annual Scientific Meeting, September, Milan, Italy. September 2017
24. Webinar: *Understanding the impact of Allergic rhinitis in the Australian Community*. Pharmacy Guild of Australia. September 2017.
25. Presentation: *Update on Australian Initiatives in Allergic rhinitis and ARIA*. AirRater Stakeholder Meeting. Hobart, Australia, 20 July 2017.
26. Symposium Presentation: *Continued innovation in respiratory care: The importance of inhaler devices*: Asian Respiratory Symposium, Guangzhou, China. 29-30 July, 2017.
27. Symposium Presentation: *Continued innovation in respiratory care: The importance of inhaler devices*: Asian Respiratory Forum, Seoul, South Korea. 1-2 July 2017.
28. Symposium Presentation: *Inhaler Devices: A critical Step*, Symposium Title: *Asthma Challenges in Clinical Practice*: European Academy of Allergy and Clinical Immunology, Helsinki, Finland, June 2017.

2016

29. Symposium Presentation "*Benefits of Intuitive Inhalers*" at the European Respiratory Society Annual Scientific Meeting Symposium "*Unmet needs in asthma and COPD: scientific advances in the treatment*", London September 2016
30. Symposium Presentation: European Respiratory Forum "*The importance of intuitive inhaler devices*" Rome, Italy June 2016
31. Symposium Presentation at the Thoracic Society of Australasia and New Zealand: "*Unraveling the inhaler maze: The importance of correct device use in respiratory management*". Perth, April 2016.
32. PSA16, Pharmaceutical Society of Australia. Interactive Workshop: "*Respiratory Pharmacy Services*"

2015

33. Symposium Presentation at the Respiratory Effectiveness Group Scientific Meeting Singapore: "*The Australian Story – inhaler devices.*"
34. Symposium Presentation European Association of Allergy and Clinical Immunology, Barcelona, Spain. "*Meeting the needs of our patients – optimising inhaler use*".
35. Symposium Presentation: European Respiratory Forum, Valencia Spain "*Generic Substitution of inhalers*"
36. Live debate against Prof Alberto Papi, European Respiratory Forum, Valencia Spain. "*The benefits of automatic substitution*"
37. Symposium presentation, New Zealand Respiratory Conference, invited by Asthma NZ, Wellington, New Zealand "*Adherence and Inhaler Technique*".
38. Symposium presentation at the *Breathing Together: 1st Respiratory Forum*, Seoul, Korea. "*Sharing best practice tools for improving clinical care*".
39. Symposium presentation at the *Breathing Together: 1st Respiratory Forum*, Seoul, Korea. "*Inhaler Handling: Matching the Device to the Patient*".

2014

40. *"Inhaler technique Mastery and Maintenance: uncovering the X-factor"*. Invited lecture Department of Respiratory Medicine, Clinical Research Centre, Royal College of Surgeons in Ireland, Beaumont Hospital and Trinity College, Ireland.
41. Invited Workshop Presenter at the International Society of Aerosols in Medicines *Bioequivalence of Inhaled Formulation and Respiratory Pediatrics Scientific Conference*. Workshop title: *Clinicians Aspects to inhaler use in Children*.

2013

42. *"Optimising medication use in asthma: skills, knowledge, motivation or patient perceptions. Where are we going wrong?"* Agency for Clinical Innovation.
43. *"Health networks: understanding the interface between patients and health care providers"* Agency for Clinical Innovation.
44. *"Respiratory – Monitoring and Data Management (Professional Service Delivery)"* Pharmacy LIVE (the Pharmaceutical Society of Australia Annual Conference)
45. Discipline of Pharmacology, School of Medical Sciences, Seminar series *"Asthma management and inhaler devices: Are we currently working together in primary health care?"*
46. *"State of the Art of Aerosol Therapy"* Thoracic Society of Australia and New Zealand, Symposium presentation, Darwin, Australia.

2012

47. Symposium presenter at Thoracic Society of Australia and New Zealand, *"Adherence and Inhaler Technique"*
48. Plenary Session, Thoracic Society of Australia and New Zealand, *"Optimising Inhaler Use"*.

2011

49. *"Collaborations in primary health care"*. School of Public Health and Community Medicine University of New South Wales, Sydney, Australia.
50. *"Inhaler devices and beyond"* Woolcock Institute of Medical Research Think Tank, Highlighting Research Symposium.

2010

51. TEVA key opinion leaders *"Inhaler Errors"* group London, UK
52. Pharmacy Guild of Australia's *"Pharmacy Practice research Summit, Translating research into Practice"*, Sydney, Australia.

2006

53. Symposium speaker: *"Increased pharmacy input into asthma care of patients in the community: from device education to disease state management"* European Respiratory Society Annual Scientific Meeting, Munich, Germany.

2004

54. Presenter representing the Faculty of Pharmacy, featured in the College of Health Sciences, University of Sydney promotion video aimed at attracting local and international students to study at the undergraduate and postgraduate level at the University of Sydney, Sydney Australia.

Consultancy and Advisory Board engagement

2020- ongoing Teva Global Digital Respiratory Medical Steering Committee

2020 –

2019 – Advisory Board Asthma Australia

2018 – ongoing AstraZeneca PRECISION Regional steering committee

PRECISION is a global, above-brand, non-promotional, and medical-led program which aims to advance clinical care in severe asthma by: accelerating referrals; building capability and capacity; and improving equity of access for severe asthma patients to specialised care and live saving treatments. As part of this program, AZ have set up a global steering committee (GSC) of international experts in addition to regional steering committees (RSC) and national working groups (NWG). I am a member of the RSC, representing the interests of pharmacy. In particular, I see it critical that as this area of practice develops, that pharmacists are enabled to have a significant clinical role.

2017 – Sanofi Australia, Paediatric Allergic Rhinitis in Australia, Chair

On behalf of Sanofi Australia I am Chairing the agenda for the Paediatric Allergic rhinitis program, which involves 7 national and international clinical experts and which will result in the publication of a large epidemiologic study exploring the prevalence and burden of allergic rhinitis in children and a publication on the burden of paediatric allergic rhinitis on health care providers: GPs and pharmacists. It is anticipated that this will provide the basis for primary care initiatives that will enhance the role of pharmacists and GPs in the management of paediatric allergic rhinitis, within a collaborative multidisciplinary process.

2017 Oversight committee for the development of Education for GPs (GSK Australia)

I was invited to take the lead in the development of several Communications modules for GPs by GlaxoSmithKline. The educational module included written material, resources, presentation slides and messages for presenter deliver. These modules include communication strategies around patient engagement and engagement with pharmacy. All other members of this committee are prescribers; GPs and respiratory specialists.

2017 – ongoing Allergic rhinitis advisor to MYLAN (formally MEDA)

I provide advice to MYLAN (formally MEDA) associated with the role of pharmacy in the management of allergic rhinitis and upper respiratory medicines use across a wide range of activities associated with the identification and treatment of allergic rhinitis in primary care.

2016 – ongoing Member of the Boehringer Ingelheim Global Advisory Board on inhaler devices

This board comprises of international recognized leaders in the field of respiratory medicines. My role on this committee is to provide expert advice on the quality use of respiratory inhalers and patient perspectives to inhaler use. I am the only pharmacist on this international board of highly esteemed leaders in respiratory research and practice.

2015 Clinical Expert on committee for the development of Education for GPs and patients (Mundipharma Australia)

I was invited to assist in the development of educational videos for inhaler device use for of the Mundipharma HCP and patient websites. I developed the educational content and identified the main messages. I also participated in the video as the inhaler technique expert.

2012 – ongoing Member of the Key International Expert Forum for TEVA Pharmaceuticals

This board is comprised of a dynamic, vibrant, esteemed group of internally-recognised leaders in the field of respiratory medical research and clinical practice. In my capacity on this board, I provide expertise on the quality use of respiratory inhalers, standards and methods of evaluation and provide feedback on emerging trends in the field. I was the only clinical pharmacist on this international board of leaders.

2015-2017 Industry lectures

I have provided consultancy on the topic of inhaler device use for the following pharmaceutical companies: TEVA, AstraZeneca, GSK, Boehringer Ingelheim and Mundipharma both nationally and internationally.

Publications

Please note since 2013, my employment has been at 0.6 FTE research and 0.4FTE Director of Development.

Scholarly book chapters

1. Basheti IA, Armour CL, Reddel HK, **Bosnic-Anticevich SZ** (2009). An Innovative Educational Module for Community Pharmacists. In Educational Evaluation: 21st Century Issues and Challenges, Editors Ortiz M and Rubio C. Nova Science Publications Inc, NY
2. Armour CL, Saini B, **Bosnic-Anticevich SZ**, Krass I (2005). Role of pharmacists in asthma monitoring. Book title "Monitoring Asthma". Editor: Prof Peter Gibson, Published by Taylor and Francis LLC (formally Marcel Dekker/CRC Press).
3. Armour CL, **Bosnic-Anticevich SZ** (2005). Respiratory Devices. Book Title: "Respiratory Therapeutic Guidelines".

Peer reviewed journal articles

2020

4. Kaplan. A, van Boven JFM, Ryan D, Tsiligianni I, **Bosnic-Anticevich S**. GINA 2020: Opportunities and challenges for primary care. Journal of. Allergy and Clinical Immunology in Practice (accepted. November 2020).
5. Evans A, Soremekun S, Stanley B, Appiagye F, Couper A, Taylor O, Le T, Pullen R, Jones S, Carter V, Pprice C, Jones R, Hancock K, **Bosnic-Anticevich S**, Ryan D, Price D. Strategies that primate sustainability in quality improvement activities for chronic disease management in healthcare settings: A Practical Perspective. Quality in Primary Care Journal (Accepted Nov 2020).
6. Serhal S, Saini B, **Bosnic-Anticevich. S**, Krass I, Wilson F, Armour C. (2020) Medication adherence in a community population with uncontrolled asthma. Pharmacy 8(4), 183.
7. Cvetkovski B, Hespe C, Tan R, Kritikos V, Azzi E, **Bosnic-Anticevich S**. (2020) General practitioner use of generically substitutable inhaler devices and the impact of training on device mastery and maintenance of correct inhaler technique. Pulmonary Therapy. <https://doi.org/10.1007/s41030-020-00131-8>
8. **Bosnic-Anticevich S**, Hespe P, Abramson M, Hespe C, Johnson M, Stodard R, Price D. Impact of allergic rhinitis on the day-to-day lives of children: Insights from an Australian cross-sectional study. BMJ Open. (October 2020).
9. Kritikos V, Price D, Chrystyn,H,, Burden, A, Thompson SL, Ryan D, Gruffydd-Jones K, Haughney J, Roche N, Lavorini F, Papi A, Infantino A, Román-Rodríguez M1, Lisspers K, Stållberg B, Høegh Henriksen S; van der Molen, **Bosnic-Anticevich S**. (2020) The burden of self-reported rhinitis and associated risk for exacerbations with moderate-severe asthma in primary care patients. Journal of Asthma and Allergy 13:415-428.
10. Soriano J, Anzueto A, **Bosnic-Anticevich S**, Miravittles M, Usmani O, Puggioni F, Canonica G, Roche N, Roche N, Kaplan A. Face masks, respiratory patients and COVID-19. European Respiratory Journal. DOI: 10.1183/13993003.03325-2020
11. Azzi E, Cvetkovski B, **Bosnic-Anticevich SZ**. Perceptions, attitudes, and behaviours of Short-acting Beta2Agonist users: an Australian cross-sectional community pharmacy-based study. Journal of Asthma (Accepted October 2020).
12. Rupasinghe M, Reath J, Cvetkovski B, Smith S, **Bosnic-Anticevich S**, Kritikos V, Abbott P. Have we got the right focus in asthma care in general practice? - a qualitative study. Australian Journal of General Practice (Accepted August 2020)
13. Dermot Ryan, Heath Heatley, Liam G. Heaney, David J. Jackson, Paul E. Pfeffer, John Busby, Andrew N. Menzies-Gow, Rupert Jones, Trung N. Tran, Mona Al-Ahmad, Vibeke Backer, Manon Belhassen, **Bosnic-Anticevich S**, Arnaud Bourdin, MD, Lakmini Bulathsinhala, Victoria Carter, Isha Chaudhry, Neva Eleangovan, J Mark FitzGerald,

- Peter G. Gibson, Naeimeh Hosseini, Alan Kaplan, Ruth B. Murray, Chin Kook Rhee, Eric Van Ganse, David Price. Potential severe asthma hidden in UK primary care. *JACI: in Practice* (Accepted October 2020)
14. Tan R, Kritikos V, Cvetkovski B, Rimmer J, Yan K, Cheong L, Bousquet J, **Bosnic-Anticevich S**. (2020) Study protocol: Development, implementation, evaluation and refinement of a translational Allergic Rhinitis Clinical Management Pathway (AR-CMaP) for community pharmacies. *Research in Social and Administrative Pharmacy*. DOI: 10.1016/j.sapharm.2020.08.009
 15. Klimek L, Jutel M, Akdis C, Bousquet J, Akdis M, Bachert C, Agache I, Ansotgui I, Bedbrook A, **Bosnic-Anticevich S**, Canonica W et al., et al., (2020) Handling of Allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. *Allergy*. DOI: 10.1111/all.14336
 16. Bousquet J, Anto JM, Bachert C, Hahtela T, Zuberbier T, Czarlewski W, Bedbrook A, **Bosnic-Anticevich S** et al. (2020) ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. *Allergy*. <https://doi.org/10.1111/all.14422>
 17. Pfaar O, Klimek L, Jutel M, Akdis CA, Bousquet J, ... **Bosnic-Anticevich S**, et al. (2020) COVID-19 pandemic: Practical considerations on the organization of an allergy clinic – an EAACI/ARIA Position Paper. *Allergy*. DOI:10.1111/all.14453
 18. Bertilsson E, Serhal S, Emmertson L, **Bosnic-Anticevich S**, Krass I, Bereznicki B, Bereznicki L, Armour C, Saini B. Pharmacists experience of and perspectives about recruiting patients into a community pharmacy asthma service trial. *Research in Social and administrative pharmacy*. DOI:10.1016/j.sapharm.2020.05.012
 19. Cvetkovski B, Cheong L, Tan R, Kritikos V, Rimmer J, Bousquet J, Yan K, **Bosnic-Anticevich S**. Qualitative exploration of pharmacists' feedback following the implementation of an 'Allergic Rhinitis Clinical Management Pathway (AR-CMaP)' in Australian community pharmacies. *Pharmacy* , 8(2), 90
 20. Lourenco O, **Bosnic-Anticevich S**, Costa E, Fonseca JA, Menditto E, Cvetkovski B, Kritikos V, Tan R, Bedbrook A, Scheire S, Bachert C, Bialek S, Briedis V, Boussery K, Canonica G, Hahtela T, Kuna P, Novellino E, Samoliński B, Schünemann H, Wallace D, Bousquet J. Managing allergic rhinitis in the Pharmacy: an ARIA proposal for implementation in practice. *Pharmacy* 8(2), e85.
 21. José J, Cvetkovski, B Kritikos V, Tan R, **Bosnic-Anticevich S**, Lourenço O. Interventions delivered in the community pharmacy to manage allergic rhinitis- a systematic review of the literature. *Pharmacy* 8(2), 80
 22. Bousquet, J, **Bosnic-Anticevich S**, Canonica GW, Anto J, Togias A, Scadding G, Salmi S, Cachert C. Allergic Rhinitis. *Nature Reviews Disease Primers* (Accepted August 2020)
 23. Bousquet J....**Bosnic-Anticevich S** et al., (202) Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. *Allergy*. DOI:10.1111/all.14302.
 24. Barbara SA, Kritikos V, Price DB, **Bosnic-Anticevich S**. (2020) Identifying patients at risk of poor asthma outcomes associated with making inhaler technique errors. *Journal of Asthma*. Mar 30:1-2.
 25. Roche N, Anzueto A, **Bosnic Anticevich S**, et al. (2020) Connected real-life research, a pillar of P4 medicine. *European Respiratory Journal*; 55: 1902287.
 26. Gibbons D, Aggarwal B, Fairburn-Beech J, Hinds D, Fletcher M, **Bosnic-Anticevich S**, Price D. (202) Treatment patterns among non-active users of maintenance asthma medication in the United Kingdom: a retrospective cohort study in the Clinical Practice Research Datalink. *Journal of Asthma*: 1-12.
 27. Kritikos V, Price D, Papi A, Infantino A, Stallberg B, Ryan D, Lavorini F, Haughney J, Lisspers K, Gruffydd-Jones K, Rodriguez M, Henrichsen, SH, van der Molen T, Carter V, **Bosnic-Anticevich S**. (2020) A multinational observational study identifying primary care patients at risk of overestimation of asthma control.. *npj Primary Care Respiratory Medicine* Jan 2020.
 28. Bedard A,...**Bosnic-Anticevich S**, et al., (2020) Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App. *Allergy*, DOI: 10.1111/all.14204.

29. Bousquet J, Bachert C, **Bosnic-Anticevich S**, Erbola M, Haahtela T, Hellings P, Kuna P, Samolinski B, Schunemann H, Wallace D. From ARIA guidelines to the digital transformation of health in rhinitis and asthma multi-morbidity. *European Respiratory Journal* 54: 1901023; DOI: 10.1183/13993003.01023-2019.
30. Bousquet, Jean, Schünemann, H. J., Togias, A. ... **Bosnic-Anticevich S** et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence." *Journal of Allergy and Clinical Immunology* (2019).
31. Bousquet, Jean, Schünemann, H. J., Togias, A. ... **Bosnic-Anticevich S** et al. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. *Clinical and translational allergy* 9.1 (2019): 1-15.
32. Bousquet, Jean, Pham-Thi, N., Bedbrook, A. ... **Bosnic-Anticevich S** et al. "Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases—Meeting Report (Part 1)." *Journal of thoracic disease* 11.8 (2019): 3633-3642
33. Bousquet, Jean, Pham-Thi, N., Bedbrook, A. ... **Bosnic-Anticevich S** et al. "Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases—Meeting Report (Part 2)." *Journal of thoracic disease* 11.9 (2019): 4072-4084
34. Bousquet J, Ansotegui IJ, Anto JM, Arnavielhe S, Bachert C, Basagaña X, Bédard A, Bedbrook A, Bonini M, **Bosnic-Anticevich S**, Braidó F. (2019) Mobile technology in allergic rhinitis: evolution in management or revolution in health and care?. *The Journal of Allergy and Clinical Immunology: In Practice*. 7.(8), 2511-2523.
35. Tan R, Cvetkovski B, Kritikos V, O'Hehir R, Lourenco O, Bousquet J, **Bosnic-Anticevich S**. Identifying an effective mobile health application for the management of allergic rhinitis and asthma. *Journal of Asthma* (2019): 1-12.
36. Cvetkovski B, Tan R, Kritikos V, Yan K, Azzi E, Srouf P, **Bosnic-Anticevich S**. Exploring the Asthma Network in People with Allergic Rhinitis Utilizing an Egocentric Social Network Analysis. *Pulmonary Therapy*. (2019): 1-11.
37. Cvetkovski, B., Kritikos, V., Yan, K., Tan, R., Azzi, E., Srouf, P., Bosnic-Anticevich, S. (2019). A qualitative investigation of the allergic rhinitis network from the perspective of the patient. *NPJ Primary Care Respiratory Medicine*, 29(1), 1-8.
38. **Bosnic-Anticevich S**. Inhaler device use: Should we just forgo the detail and go for the 'big picture' approach? *Respirology* 24.10 (2019): 924-925.
39. Bousquet J, Bedbrook A, Czaerlewski ...**Bosnic-Anticevich S** et al., (2019). Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. *Clinical and Translational Allergy*. 6:16. <https://doi.org/10.1186/s13601-019-0252-0>.
40. Srouf-Alphonse P, Cvetkovski B, Rand C, Azzi E, Tan R, Kritikos V, **Bosnic-Anticevich S** (2019). It takes a village - asthma networks utilised by parents when managing childhood asthma medications. *Journal of Asthma*. <https://doi.org/10.1080/02770903.2019.1568456>
41. Bousquet J, Hellings P, Agache I, Amat F...**Bosnic-Anticevich** et al., (2019) Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. *Journal of Allergy and Clinical Immunology*. 143 (3), 864-879.
42. Bousquet J, Pfaar O, Togias A, Schunemann HJ, Ansotegui I, Papadopoulos NG, Tsiligianni I, Agache I, Anto JM, Bachert C, Nedbrook A, Bergmann KC, **Bosnic-Anticevich S** et al., (2019) ARIA 2019 Care pathways for allergen immunotherapy. *Allergy*. <https://doi.org/10.1111/all.13805>
43. Bédard A, Basagaña X, Anto JM, Garcia-Aymerich J, Devillier P, Arnavielhe S, **Bosnic-Anticevich S** et al., (2019). Mobile technology offers novel insights on control and treatment of allergic rhinitis. The MASK study. *Journal of Allergy and Clinical Immunology*. *Journal of Allergy and Clinical Immunology*, <https://doi.org/10.1016/j.jaci.2019.01.053>

44. Azzi E, Kritikos V, Peters M, Price D, Srouf P, Cvetkovski B, **Bosnic-Anticevich S**. Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey *BMJ open* 9.8 (2019): e028995.
45. Price, D. B., **Bosnic-Anticevich, S.**, Pavord, I. D., Roche, N., Halpin, D. M., Bjermer, L., ... & Rastogi, S. (2019). Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. *Clinical and Translational Allergy*, 9(1), 41.
46. Roche, N., Anzueto, A., **Bosnic-Anticevich, S**, Kaplan, A., Miravittles, M., Ryan, D., ... & Canonica, G. W. (2019). The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group: Endorsed by the International Primary Care Respiratory Group and the World Allergy Organization. *European Respiratory Journal*. 2019 54: 1901511. <http://doi.org/10.1183/13993003.01511-2019>.
47. O'Dwyer, S., Greene, G., MacHale, E., Cushen, B., Sulaiman, I., Boland, F., **Bosnic-Anticevich, S.**, et al. (2019). Personalized Biofeedback on Inhaler Adherence and Technique by Community Pharmacists: A Cluster Randomized Clinical Trial. *The Journal of Allergy and Clinical Immunology: In Practice*.

2018

48. **Bosnic-Anticevich S**. (2018) Continued innovation in respiratory care: The importance of inhaler devices. *Tuberculosis and Respiratory Diseases. Journal of Tuberculosis and Respiratory Disease*, 8 (2), 91-98.
49. **Bosnic-Anticevich S**, Cvetkovski B, Azzi EA, Srouf P, Tan R, Kritikos V (2018) Identifying Critical Errors: Addressing Inhaler Technique in the Context of Asthma Management. *Pulmonary Therapy*, 4 (1), 1-12.
50. Menditto E, Costa E, Midao L, **Bosnic-Anticevich S et al** (2018) Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study. *Clinical and Experimental Allergy* DOI: 10.1111/cae.13333
51. Bousquet J, Arnavielhe S, Bedrook A, Fonseca J, Morais Almeida M, Todo Bom, A, Annesi-Maesano I, Caimmi D, Demoly P, Devillier P, Siroux V, Menditto E, Passalacqua G, Stellato C, Ventura MT, Cruz AA, Sarquis Serpa F, ...**Bosnic-Anticevich S**, et al., (2018) The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. *Allergy*, 73 (2), 505-510.
52. Bousquet J, Hellings, PW, Agache I, Amat F, Annesi-Maesano I, Ansotegui IJ, Anto JM, Bachert C, Bateman ED, Bedbrook A, Bennoor K, Bewick M, Bindeslev-Jensen C, **Bosnic-Anticevich S** et al., (2019) Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. *Journal of Allergy and Clinical Immunology*, 143 (3), 864-879
53. Price D, Yang S, Mong SWY, Hardjojo A, Cabrera C, Papaionnou AI, 864-879. Loukides S, Kritikos V, **Bosnic-Anticevich S**, Carter V, Dorinsky PM. Physiological predictors Of peak inspiratory flow using Observed lung function results (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation. *International Journal of COPD*. 13; 13:3937-3946. Doi 10.2147/COPD.S174371.
54. **Bosnic-Anticevich S**, Costa E, Menditto E, et al. ARIA pharmacy 2018: Allergic rhinitis care pathways for community pharmacy. *Allergy* <https://doi.org/10.1111/all.13701>
55. Bousquet J, ... **Bosnic-Anticevich S** et al., (2018) MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. *Clinical and Translational Allergy*, 8:45. <https://doi.org/10.1186/s13601-018-0227-6>
56. Tan R, Cvetkovski B, Kritikos V, Yan K, Price D, Smith P, **Bosnic-Anticevich S**. (2018) Management of allergic rhinitis in the community pharmacy: identifying the reasons behind medication self-selection. *Pharmacy Practice*, 16(3), doi: [10.18549/PharmPract.2018.03.1332](https://doi.org/10.18549/PharmPract.2018.03.1332).
57. Samret D, Arnavielhe S, Ingenrieth F, Bedrook A, Onorato G, Murray R, Almeida R, Mizani M, ...**Bosnic-Anticevich S** et al., (2018) Geolocation with respect to personal privacy for the Allergy Diary App- A MASK study *World Allergy Organization Journal* 11:15, <https://doi.org/10.1186/s40413-018-0194-3>

58. Courbis AL; Murray R; Arnavielhe S; Caimmi D; Bedbrook A; van Eerd, M; De Vries, G; Dray, G; Agache, I; Morais-Almeida, M; Bachert, C; Bergmann, C; **Bosnic-Anticevich, S**; Brozek, J; Bucca, C; Camargos, PA; Canonica, G; Carr, W; Casale, T; Fonseca, J.(2018) Electronic Clinical Decision Support System for allergic rhinitis management. *Clinical and Experimental Allergy*. DOI: 10.1111/cea.13230
59. Price DB, Thomas V, Dekhuijzen R, **Bosnic-Anticevich S**, Roche N, et al. Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study. *BMC Pulm Med* 2018;18:107.
60. # Toumas-Shehata M, Henricks M, Ovchinnikova L, Smith L and **Bosnic-Anticevich SZ**. Teaching pharmacy undergraduate students Inhaler device technique and exploring factors affecting maintenance of technique. *Canadian Respiratory Journal*. Article ID 1597217/ doi.org/10.1155/2018/1597217
61. Price DB, Smith PK, Harvey R, Carney AS, Kritikos V, **Bosnic-Anticevich S**, Christian L, Skinner D, Carter V, Durieux AMS. (2018) Real-life treatment of rhinitis in Australia; a historical cohort study of prescription and over-the-counter therapies". *Pragmatic and Observational Research*; 9, 43-54.
62. Cvetkovski B, Kritikos V, Yan K, **Bosnic-Anticevich S**. (2018) Tell me about your hay fever: A qualitative investigation of allergic rhinitis management from the perspective of the patient. *nPJ Primary Care Respiratory Medicine* 28, 3, doi:10.1038/s41533-018-0071-0.
63. Tan R, Cvetkovski B, Kritikos V, Yan K, Price D, Smith P, **Bosnic-Anticevich S**. The burden of rhinitis and the impact of medication management within the community pharmacy setting. *Journal of Allergy and Clinical Immunology: In Practice*. 6(5), 1717-1725. <https://doi.org/10.1016/j.jaip.2018.01.028>
64. Dobler C, **Bosnic-Anticevich S**, Armour C. Physicians' perspectives on communication and decision making in clinical encounters for treatment of latent tuberculosis infection. *European Respiratory Journal Open Research* DOI: 10.1183/23120541.00146-2017.
65. Bousquet J, Arnavielhe S, Bedbrook A, Alexis-Alexandre G, van Eerd M, Murray R, Canonica GW, Illario M, Menditto E, Passalacqua G, Stellato C, Triggiani M, Carreiro-Martins P, Fonseca J, Morais Almeida M, Nogueira-Silva L, Pereira AM, Todo Bom A, Bosse I, Caimmi D, Demoly P, Devillier P, Fontaine JF, Just J, Onorato GL, Kowalski ML, Kuna P, Samolinski B, Anto JM, Mullol J, Valero A, Tomazic PV...**Bosnic-Anticevich S** et al., (2018). Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study. *Allergy*. <https://doi.org/10.1111/all.13406>
66. **Bosnic-Anticevich S**, Callin C, Chrystyn H, Lavorini F, Nikolaou V, Kritikos V, Dekhuijzen PNR, Roche N, Bjermer L, Rand C, Zwar N, Price D. (2018) Inhaler technique mastery and maintenance in healthcare professionals trained on different devices. *Journal of Asthma*, 55(1), 79-88.
67. **Bosnic-Anticevich S**, Yan K, Price D, Carter V, Chrystyn H, Kritikos V (2018) Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed dose combination therapy in Australia. *Journal of Asthma*. 55(6), 684-694.
68. Bousquet J, Devillier P, Anto JM, Bewick M, ...**Bosnic-Anticevich S**...et al., (2018) Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study. *Allergy*. <https://doi.org/10.1111/all.13448>
69. Bousquet, J., Schunemann, H., Hellings, P., Arnavielhe, S., Bachert, C., Bedbrook, A., Bergmann, K., Bosnic-Anticevich, S., Brozek, J., Calderon, M., et al (2016). MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 138(2), 367-374.e2.
70. Bousquet, J., Farrell, J., Crooks, G., Hellings, P., Bel, E., Bewick, M., Chavannes, N., Correia de Sousa, J., Cruz, A., Bosnic-Anticevich, S., Jenkins, C., et al (2016). Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). *Clinical and Translational Allergy*, 6(1), 1-18.

71. Chrystyn H, Benhaddi H, van der Tol M, Voorham J, Haughney J, **Bosnic-Anticevich S**, Price D, Roche N. (2017) Comparing asthma and COPD inhaler devices in real life clinical practice in the UK: differences in training requirements and preferences. *European Respiratory Journal*: DOI: 10.1183/1393003
72. Hellings J, **Bosnic-Anticevich S** et al., (2017) Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. *Allergy*, 72 (9), 1297-1305.
73. Tan R, Cvetkovski B, Kritikos V, Yan K, Price D, Smith P, **Bosnic-Anticevich S**. (2017) Identifying the hidden burden of Allergic Rhinitis (AR) in community pharmacy: a global phenomenon. *Asthma Research and Practice*. DOI 10.1186/s40733-017-0036-z.
74. Bousquet et al. Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire using Mobile Technology: The MASK study. *Journal of Investigational Allergology and Clinical Immunology. Practitioner's Corner Vol 28 [1], 2018* DOI 10.18176/jiaci.0197
75. Barbara S, Kritikos V, **Bosnic-Anticevich S**. Inhaler technique: does age matter? A systematic review. *European Respiratory Review* 26(146), 1-10.
76. # Tsingos-Lucas C, MCentee M, **Bosnic-Anticevich S**, Schneider C, Bartimore-Aufflick K, Smith L. Inter-rater reliability of a reflective rubric to assess pharmacy students' reflective thinking. *Currents in Pharmacy Teaching and Learning*, 9(6), 989-995 <https://doi.org/10.1016/j.cptl.2017.07.025>
77. **Bosnic-Anticevich S**, Yan K, Price D, Carter V, Chrystyn H, Kritikos V (2017) Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed dose combination therapy in Australia. *Journal of Asthma* <http://dx.doi.org/10.1080/02770903.2017.1353611>
78. Bousquet J, Bewick M, Amavielhe S, Mathieu-Dupos E, Murray R, Bedbrook A, Caimmi DP, Vandenplas O, Hellings PW, Bachert C, Anto JM, Bergmann KC, Bindslev-Jensen C, **Bosnic-Anticevich S**, Bouchard J, Canonica GW, Chavannes NH, Cruz AA, Dahl R, Demoly P, De Vries G, Devillier P, Fink-Wagner A, Fokkens WJ, Fonseca J, Guldmond NA, Haahtela T, Hellqvist-Dahl B, Just J, Keil T, Klimek L, Kowalski ML, Kuna P, Kvedariene V, Laune D, Larenas-Linnemann D, Mullol J, Pereira AM, Carreiro-Martins P, Melen E, Morais-Almeida M, Nogueira-Silva L, O'Hehir RE, Papadopoulos NG, Passalacqua G, Portejoie F, Price D, Ryan D, Samolinski B, Sheikh A, Simons FER, Spranger O, Todo Bom A, Tomazic PV, Triggiani M, Valero A, Valvirta E, Valiulis A, van Eerd M, Wickman M, Young I, Zuberbier T. (2017) Work Productivity in rhinitis using cell phones: The MASK pilot study, *Allergy*, 72 (10); 1475-1484.
79. Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, **Bosnic-Anticevich S**, et al., Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. *Journal of Allergy and Clinical Immunology* (in press). 140(4), 950-958.
80. Bousquet J, Agache I, Aliberti MR, Angles R, Annesi-Maesano I, Anto JM, Arnavielhe, Asayag E, Bacci E, Bedbrook A, Bachert C, Baroni I, Barreto BA, Bedolla-Barajas M, Bergmann KC, Bertorello L, Bewick M, Bieber T, Birov S, Bindslev-Jensen C, Blua A, Bochenska Marciniak M, Bogus-Buczynska I, **Bosnic-Anticevich S** et al., Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - Reference Site Twinning (EIP on AHA). *Allergy*. 73(1), 77-92.DOI 10.1111/all.13218.
81. Smith P, Price D, Harvey R, Carney AS, Kritikos V, **Bosnic-Anticevich SZ**, Christian L, Skinner D, Carter V, Durieux AMS. (2017) Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases. *Journal of Asthma and Allergy* 10, 153-161.doi: 10.2147/JAA.S128431
82. Fuller J, Saini B, **Bosnic-Anticevich S**, Garcia-Cardenas V, Armour C. (2017) Testing evidence for Routine Practice: Using an implementation framework to embed a clinically proven asthma service in Australian community pharmacy. *Research in Social and Administrative Pharmacy*. 13, 898-996.
83. Carney S, Price D, Smith P, Harvey R, Kritikos V, **Bosnic-Anticevich S**, Christian L, Skinner D, Carter V, Durieux A. (2017) Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study *Journal: Pragmatic and Observational Research*. 8, 157-165.

84. Elaro, A, **Bosnic-Anticevich S**, Kraus K, Farris K, Shah S, Armour C, Patel M. Understanding pharmacists' management of pediatric asthma in the southeast Michigan community pharmacy setting. *International Journal of Clinical Pharmacy* DOI 10.1007/s11096-017-0471-1.
85. Azzi E, Srouf P, Armour C, Rand C, **Bosnic-Anticevich S**. (2017) Practice Makes Perfect: Self-Reported Adherence a Positive Marker of Inhaler Technique Maintenance. *Journal of Asthma* doi:10.1038/s41533-017-0031-0
86. Smith P, Price D, Harvey R, Carney AS, Kritikos V, **Bosnic-Anticevich S**, Christian L, Skinner¹ D, Carter V, Durieux A. (2017) Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases. *Journal of Asthma and Allergy*, 10: 153-161.
87. # Tsingos-Lucas C, **Bosnic-Anticevich S**, Schneider CR, Smith L. (2017) Using Reflective Writing as a Predictor of Academic Success in different assessment formats. *American Journal of Pharmaceutical Education* 81(1): Article 8, 1- 8.
88. **Bosnic-Anticevich SZ**. Inhaler device handling: Have we really started to address the problem? *European Respiratory Journal*. (2017); 49:1700120
89. Price D; Miguel Roman-Rodriguez; Brett McQueen; Sinthia **Bosnic-Anticevich**; Victoria Carter; Kevin Gruffydd-Jones; John Haughney; Svein Henrichsen; Catherine Hutton; Antonio Infantino; Federico Lavorini; Lisa M Law; Karin Lisspers; Alberto Papi; Dermot Ryan; Björn Stållberg; Thys van der Molen; Henry Chrystyn. (2017) Inhaler errors in the CRITIKAL study: type, frequency and association with asthma outcomes. *Journal of Allergy and Clinical Immunology: In Practice*, 5(4), 1071-1081. <https://doi.org/10.1016/j.jaip.2017.01.004>
90. Jahedi L, Downie S, Saini B, Chan HK, **Bosnic-Anticevich S**. Inhaler Technique in Asthma: How Does It Relate to Patients' Preferences and Attitudes Toward Their Inhalers? *Journal of Aerosol Medicine and Pulmonary Drug Delivery*. (2017) Feb1:30 (1):42-52
91. **Bosnic-Anticevich S**, Chrystyn H, Costello R, Dolovich M, Fletcher M, Lavorini F, Rodriguez-Roisin R, Ryan D, Ming SWY, Skinner D, Price D. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. *International Journal of COPD*. (2017): 12; p59-7.
92. Bousquet, J., Onorato, G., Bachert, C., Barbolini, M., Bedbrook, A., Bjermer, L., Correia de Sousa, J., Chavannes, N., Cruz, A., Bosnic-Anticevich, S., et al (2017). CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel Network) Good Practice in allergic rhinitis: A SUNFRAIL report. *Clinical and Translational Allergy*, 7(37), 1-16.
93. Basheti, I., Hammad, E., Bosnic-Anticevich, S. (2017). Economic impact of inhaler misuse in Australia and Jordan: Checklist guided patient education can reduce pharmaceutical expenditures. *Jordan Journal of Pharmaceutical Sciences*, 10(2), 113-126.

2016

94. Bousquet J, Agache I, Bedbrook A, Bachert C, Bergmann K, Bewick M, Bindselev-Jensen C, **Bosnic-Anticevich S** et al. (2016) ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. *Clinical and Translational Allergy*. 6:47, DOI: 10.1186/s13601-016-0137-4
95. Dekhuijzen R, Batsiou M, Bjermer L, **Bosnic-Anticevich S**, Chrystyn H, Papi A, Rodríguez-Roisin R, Fletcher M, Wood L, Cifra A, Soriano JB, Price DB. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device. *Respiratory Medicine*. 120:54-63.
96. # Tsingos C, **Bosnic-Anticevich ZS**, Smith L. A Retrospective Study on Students' and Teachers' Perceptions of the Reflective Ability Clinical Assessment (RACA) (2016). *American Journal of Pharmaceutical Education*, 80 (6) Article 101
97. Briado F, Chrystyn H, Baiardini I, **Bosnic-Anticevich S**, van der Molen T, Dandurand R, Chisholm A, Carter V, Price D on behalf of the Respiratory Effectiveness Group. (2016) "Trying, but failing"- The role of inhaler technique and mode of delivery in respiratory medication adherence. *Journal of Allergy and Clinical Immunology*, 4(5), 823-832.

98. # Tsingos C, **Bosnic-Anticevich SZ**, Schneider C, Smith L. (2015) The Effect of Reflective Activities in Reflective Thinking Ability in an Undergraduate Pharmacy Curriculum. *American Journal of Pharmaceutical Education*, 80(4); 65.
99. O'Dwyer SM, MacHale E, Sulaiman I, Holmes M, Hughes C, D'Arcy S, Rapcan V, Taylor T, Boland F, **Bosnic-Anticevich S**, Reilly RB, Ryder SA, Costello RW (2016) The effect of providing feedback on inhaler technique and adherence from an electronic audio recording device, INCA[®], in a community pharmacy setting: study protocol for a randomised control trial. *Trials* 17(1), 1-9.
100. **Bosnic-Anticevich S**, Mavritsakis S, Hoe S, Young PM, Traini D. (2016) Substitute and add-on devices used in inhalation therapy: is it safe to recommend replacing the VentoinTM actuator with the Sports-HalerTM. *Drug Delivery Letters* 6 | DOI: 10.1183/13993003.00240-2016.
101. **Bosnic-Anticevich SZ**. Asthma Management in primary care: caring, sharing and working together. *European Respiratory Journal*. 47:1043-1046 | DOI: 10.1183/13993003.00240-2016.
102. Chrystyn H, Price D, Molimard M, Haughney J, **Bosnic-Anticevich S**, Lavorini F, Efthimiou J, Shan D, Sims E, Burden A, Hutton C, Roche N. (2016) Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study. *BMC Pulmonary Medicine*. 16:12 | DOI: 10.1186/s12890-016-0169-5.

2015

103. Davis S, Durvasula S, Merhi D, Young P, Traini D, **Bosnic-Anticevich S**. (2015) Knowledge that people with intellectual disability have of their inhaled asthma medications-messages for pharmacists. *International Journal of Clinical Pharmacy*. 38(1),135-143.
104. Bousquet J, Schunemann HJ, Fonseca J, Samolinski B, Bachert C, Canonica GW, **Bosnic-Anticevich S** et al. (2015) MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): The new generation guideline implementation. *Allergy*. 70, 1372-1392.
105. Tsingos C, **Bosnic-Anticevich S**, Smith L. (2015) Does a learning style preference for processing information through reflection impact on the academic performance of a cohort of undergraduate pharmacy students? *Pharmacy Education*, 15(1) 233-240.
106. Westerik JA, Carter V, Chrystyn,H, Burden, A, Thompson SL, Ryan D, Gruffydd-Jones K, Haughney J, Roche N, Lavorini F, Papi A, Infantino A, Román-Rodríguez M, **Bosnic-Anticevich S**, Lisspers K, Stållberg B, Høegh Henriksen S; van der Molen T, Hutton C, Price D. On behalf of the iHARP working group. (2015) Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting. *Journal of Asthma* 53(3): 321-329
107. # Tsingos C, **Bosnic-Anticevich SZ**, Lonie J, Smith L. A model for assessing reflective practices in pharmacy education. *American Journal of Pharmacy Education* 79(8): 124
108. Davis S, Durvasula S, Merhi D, Traini D, Young P, **Bosnic-Anticevich S** (2015) The ability of people with intellectual disability to use inhalers – an exploratory mixed methods study. *Journal of Asthma*. 53(1): 86-93.
109. LeMay K, Saini B, Smith LD, **Bosnic-Anticevich SZ**, Song YJ, Alles MC, Burton DL, Emmerton L, Stewart K, Krass I. Armour CL. (2015) An exploration of clinical interventions provided by pharmacists within a complex asthma service. *Pharmacy Practice* 13(1): 529.
110. Elaro A, Shah S, Armour C, **Bosnic-Anticevich S**. (2015) A snapshot of pharmacist attitudes and behaviours surrounding the management of paediatric asthma. *Journal of Asthma*. 52(9):957-68
111. Davis S, Durvasula S, Merhi D, Traini D, Young P, **Bosnic-Anticevich S** (2015) Unique location but similar issues - working with health professionals in correctional services to improve inhaler use. *Journal of Pharmacy Practice and Research*, 45(3), 276-281.
112. Burton DL, LeMay KS, Saini B, Smith L, **Bosnic-Anticevich S**, Southwell P, Cooke J, Emmerton L, Stewart K, Krass I, Reddel H, Armour C. (2015) The reliability and utility

- of spirometry performed on people with asthma in community pharmacies *Journal of Asthma*. 52(9):913-9.
113. Davis S, Durvasula S, Merhi D, Traini D, Young P, **Bosnic-Anticevich S**. (2015) The role of direct support professionals in asthma management. *Journal of Intellectual & Developmental Disability*. 40(4): 342-353. <http://dx.doi.org/10.3109/13668250.2015.1041100>
 114. Naik-Panvelkar P, Saini B, LeMay K, Emmerton L, Stewart K, Burton D, **Bosnic-Anticevich SZ**, Krass I, Smith L and Armour CL. (2015) A pharmacy asthma service achieves a change in patient responses from increased awareness to taking responsibility for their asthma. *International Journal of Pharmacy Practice*. 23 (3) 182-191.
 115. Basheti IA, Natsheh AI, Ammari WG, Khater S, Qunaibi EA, **Bosnic-Anticevich S** (2015). Education on Correct Inhaler Technique in Pharmacy Schools: Barriers and Needs. *Tropical Journal of Pharmaceutical Research*. 14(4):715-722
 116. Tsingos, C., Bosnic-Anticevich, S., Smith, L. (2015). Learning styles and approaches: Can reflective strategies encourage deep learning? *Currents in Pharmacy Teaching and Learning*, 7(4), 492-504. [\[More Information\]](#)
 117. Cheong L, Armour C, **Bosnic-Anticevich SZ**. (2015) Patient asthma networks: understanding who is important and why. *Health Expectations* 18(6):2595-2605.

2014

118. Elaro A, Pomare L, Shah S, Armour C, **Bosnic-Anticevich S**.(2014) PACE: Pharmacists use the power of communication in paediatric asthma. *International Journal of Clinical Pharmacy* 36:976-985
119. # **Bosnic-Anticevich, SZ**, Stuart M, Cvetkovski B, Sainsbury E, Armour C, Mavritsakis S, Mendrela G, Travers-Mason G, Williamson M. (2014) Development and evaluation of an innovative model of inter-professional education focused on asthma medication use. *BMC Medical Education* 14:72, <http://www.biomedcentral.com/1472-6920/14/72>.
120. # Toumas-Shehata M, Price D, Basheti I, **Bosnic-Anticevich SZ**. (2014) Exploring the role of quantitative feedback in inhaler technique education: a cluster-randomised, two-arm, parallel group, repeated measures study. *njp Primary Care Respiratory Journal*, 24, 14071, doi: 10.1038/npjcrm.2014.71
121. Price D, Bateman, ED, Chisholm A, Papadopoulos NG, **Bosnic-Anticevich S**, Pizzichini E, Hillyer AV, Buist S. (2014) Complementing the Randomised Controlled trial Evidence Base: Evolution not Revolution. *Annals of The American Thoracic Society* 11 (suppl 2) S92-S98
122. Basheti I, **Bosnic-Anticevich S**, Armour C, Reddel H. (2014) Checklists for dry powder inhaler technique: a review and recommendations. *Respiratory Care*. Published ahead of print October 15, 2013, doi: 10.4187/respcare.02342.
123. # Tsingos C, **Bosnic-Anticevich SZ**, Smith L. (2014) Reflective practice and its implications for pharmacy education. *American Journal of Pharmaceutical Education* 78(1): 18.

2013

124. Smith L, Alles C, Le May, K, Reddel, H, Saini B, **Bosnic-Anticevich S**, Emmerton L, Stewart K, Burton D, Krass I, Armour C. (2013) The contribution of goal specificity to goal achievement in collaborative goal-setting for the management of asthma. *Research in Social and Administrative Pharmacy* 9(6), 918–929
125. Davis S, Durvasula S, Merhi D, Traini D, Young P, **Bosnic-Anticevich S**. (2013) Respiratory medication use in an Australian developmental disability clinic population: messages for health care professionals. *Australian Journal of Primary Health*. 20(3):278-284. <http://dx.doi.org/10.1071/PY12153>.
126. Cheong L, Armour C, **Bosnic-Anticevich SZ**. (2013) Primary health care teams and the patient perspective: a social network analysis. *Research in Social and Administrative Pharmacy*. 9 (6), 741-75.

127. Armour CL, Reddel HK, LeMay KS, Saini B, Smith LD, **Bosnic-Anticevich SZ**, Song YJ, Alles MC, Burton DL, Emmerton L, Stewart K, Krass I. (2013) Feasibility and effectiveness of an evidence-based asthma service in Australian community pharmacies: a pragmatic cluster randomised trial: *Journal of Asthma*, 50(3): 302-9.
128. # Smith L, Brown L, Bundy A, Ronaldson W, McKenzie H, Lewis P, **Bosnic-Anticevich SZ**. (2013) A Learning and Teaching Resource on Patient Self-Management of Chronic Pain *American Journal of Pharmacy Education*, 77, 35.
129. Price D, **Bosnic-Anticevich S**, Briggs A, Chrystyn H, Rand C, Scheuch G, Bousquet J, Inhaler Error Steering Committee (2013) Inhaler Competence in Asthma: Common errors, barriers to use and recommended solutions. *Respiratory Medicine*. 107: 37-43.
130. Donnelly A, Shah S, **Bosnic-Anticevich S** (2013) Effect of two educational interventions on pharmacy students' confidence and skills in dealing with adolescents with asthma. *Health Education Journal*. 72(2) 222–229.
131. Cheong L, Armour C, **Bosnic-Anticevich SZ** (2013). Multidisciplinary Collaboration in Primary care: through the eyes of Patients. *Australian Journal of Primary Health*, 19(3) 190-197. <http://dx.doi.org/10.1071/PY12019>.

2012

132. Emmerton L, Smith LD, LeMay KS, Krass I, Saini B, **Bosnic-Anticevich SZ**, Reddel HK, Burton DL, Stewart K and Armour CL. (2012) Experiences of pharmacists involved in the delivery of a specialist asthma service in Australia *BMC Health Services Research*. 12 (1):164 doi: 10.1186/1472-6963-12-164.
133. Foster JM, Smith L, **Bosnic-Anticevich SZ**, Usherwood T, Sawyer SM, Rand CS, Reddel HK. (2012) Identifying patient-specific beliefs and behaviours for conversations about adherence in asthma. *Internal Medicine Journal*. Jun;42(6):e136-e144. doi: 10.1111/j.1445-5994.2011.02541.x.

2011

134. Dey, RM, Wiggers de Vries, MJW, **Bosnic-Anticevich SZ**. (2011) Collaboration in chronic care: unpacking the relationship of pharmacists and general medical practitioners in primary care. *International Journal of Pharmacy Practice*. 19 (1), 21-29
135. Saini B, Shah S, Kearey P, **Bosnic-Anticevich S**, Grootjans J, Armour C. (2011) An interprofessional learning module on asthma health promotion. *American Journal of Pharmaceutical Education* 83(3): 295-302.
136. Saini B, LeMay K, Emmerton L, Krass I, Smith L, **Bosnic-Anticevich S**, Stewart K, Burton D, Armour C. (2011) Asthma disease management – Australian pharmacists' interventions improve patients' asthma knowledge and this is sustained.(2011) Patient Education and Counseling dx.doi.org/10.1016/j.pec.2011.05.001.
137. Basheti I, Qunaibi E, Armour C, **Bosnic-Anticevich S**, Khatar S, Reddel H. (2011) User Error With Diskus and Turbuhaler by Asthma Patients and Pharmacists in Jordan and Australia. *Respiratory Care* 56(12), 1916-1923.
138. Saini B, **Bosnic-Anticevich SZ**, Smith L, Krass, I, Armour C. (2011) Role of community pharmacists in asthma – Australian research highlighting pathways for future primary care models. *Australasian Medical Journal* 4, 190-200.
139. Ovchinnikova L, Smith L, **Bosnic-Anticevich S**. (2011) "Inhaler technique maintenance: gaining an understanding from the patients' perspective". *Journal of Asthma* 48, (6) 616-624.
140. Abdelnour M, Armour C, Reddel H, **Bosnic-Anticevich S**. (2011) Multidisciplinary Asthma Care Teams: the role of the specialist pharmacist. *Australian Pharmacist* 30,686-691.
141. Goeman D, Jenkins C, Crane M, **Bosnic-Anticevich S**, Douglas J. (2011) Unmet needs of older people with asthma cross sectional survey. *Journal of Asthma*, 48 (9), 865-875: 865-875.
142. Armour C, LeMay K, Saini B, Reddel H, **Bosnic-Anticevich S**, Smith L, Burton D, Song Y, Alles C, Stewart K, Emmerton L, Krass I. (2011) Using the community pharmacy to indentify patient at risk of poor asthma control and factors which contribute to this poor control. *Journal of Asthma* 48:914–922.

2010

143. **Bosnic-Anticevich SZ**, Sinha H, So S, Reddel HK (2010). Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. *Journal of Asthma*. 47, 251-256
144. Kritikos V, Reddel HK, and **Bosnic-Anticevich SZ**. (2010) Pharmacists' Perceptions of their Role in Asthma Management and Barriers to the Provision of Asthma Services. *International Journal of Pharmacy Practice*. 18: 209-216.
145. Nguyen YBN, Wainwright C, Basheti IA, Willis M, **Bosnic-Anticevich SZ** (2010) Do Health Professionals on Respiratory Wards know how to use inhaler? *Journal of Pharmacy Practice and Research*, 2010: 40(3): 211-216.

2009

146. Basheti I, Armour CL, Reddel HK, **Bosnic-Anticevich SZ** (2009). Long-term maintenance of pharmacists' inhaler technique: applying focused educational tools. *American Journal of Pharmaceutical Education*. 73(2):32
147. # Toumas M, Basheti IA, **Bosnic-Anticevich SZ** (2009). Comparison of small-group training with self-directed internet-based training in inhaler techniques. *American Journal of Pharmaceutical Education*. 73(5). Article 85.
148. Cvetkovski B, Armour CL, **Bosnic-Anticevich SZ** (2009). Asthma Management in Rural NSW; Perceptions of Health Care Professionals and People with Asthma. *Australian Journal of Rural Health*. 17, 195–200.

2008

149. Saini B, Filipovska J, Krass I, Taylor S, **Bosnic-Anticevich S**, Armour C (2008). An Evaluation of a community pharmacy based rural asthma management service. *Australian Journal of Rural Health*. 16 (2), 100-108.
150. Basheti IA, Armour CL, **Bosnic-Anticevich SZ**, and Reddel HK (2008). Evaluation of a novel educational strategy, including inhaler-based reminder labels, to improve asthma inhaler technique. *Patient Education and Counseling*. 72: 26-33
151. O'Connor J. Seeto C. Saini B. **Bosnic-Anticevich S**. Krass I. Armour C. Smith L (2008). Healthcare professional versus patient goal setting in intermittent allergic rhinitis. *Patient Education and Counseling*. 70(1):111-7, 2008
152. Reddel HK. **Bosnic-Anticevich SZ**. Amour CL. Basheti I (2008). Pharmacist interventions in asthma. *European Respiratory Journal*. 32(3):812.
153. **Bosnic-Anticevich SZ** (2008). Book Review "Gilbaldi's Drug Delivery Systems in Pharmaceutical Care". *The Annals of Pharmacotherapy*. 42

2007

154. Smith, L., **Bosnic-Anticevich, S.**, Mitchell, B., Krass, I., Saini, B., & Armour, C. A (2007). Treating asthma with a Self-Management Model of Illness Behaviour in an Australian Community Pharmacy Setting. *Social Science & Medicine*. 64 (7): 1501 – 1511.
155. Kritikos V, Armour CL, **Bosnic-Anticevich SZ** (2007). Interactive Small-Group Asthma Education in the Community Pharmacy Setting: A Pilot Study. *Journal of Asthma*. 44(1): 57-64.
156. Armour C, **Bosnic-Anticevich S**, Brilliant M, Burton D, Emmerton L, Krass I, Saini B, Smith L, Stewart K, (2007) Pharmacy asthma care program (PACP) improves outcomes for patients in the community. *Thorax*, 62(6):496-592.
157. Basheti I, Reddel HK, Armour CL, **Bosnic-Anticevich SZ** (2007). Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. *Journal of Allergy and Clinical Immunology*, 119 (6), 1537-1538
158. Smith L, Saini B, Krass I, Chen T, **Bosnic-Anticevich S**, Sainsbury E. (2007) Pharmacy students' approaches to learning in an Australian university. *American Journal of Pharmaceutical Education*. 71(6), 120.
159. Gordoïs A, Armour C, Brilliant M, **Bosnic-Anticevich S**, Burton D, Emmerton L, Krass I, Saini B, Smith L, Stewart K (2007). Cost effectiveness analysis of a Pharmacy

Asthma Care Program in Australia. *Disease Management and Health Outcomes*. 15(6), 387-396.

160. **Bosnic-Anticevich SZ** (2007). Asthma in Focus. *The Annals of Pharmacotherapy* Published Online First: May 2007. DOI 10.1345/aph.1K032.

2006

161. Slader CA, Reddel HK, Spencer LM, Belousova EG, Armour CL, **Bosnic-Anticevich SZ**, Thien FCK, and Jenkins CR (2006). Double blind randomised controlled trial of two different breathing techniques in the management of asthma. *Thorax* 61(8): 651-656
162. Belousova E, Armour C, **Bosnic-Anticevich S**, Jenkins C, Slader C, Reddel H, Spencer L, Thien F (2006). Double blind randomised controlled trial of two different breathing techniques in the management of asthma. *Thorax*. 61 (2), 651-656.
163. Armour, C., Krass, I., Hulme, F., Dalton, A., Saini, B., Filipovska, J., Bosnic-Anticevich, S., Taylor, S. (2006). ABS71: An evaluation of a community pharmacy based rural asthma management service. *Primary Care Respiratory Journal*, 15(3), 205-205.
164. Slader, C., Reddel, H., Jenkins, C., Armour, C., Bosnic-Anticevich, S. (2006). Complementary and alternative medicine use in asthma: Who is using what? *Respirology*, 11(4), 373-387.

2005

165. Basheti IA, Reddel HK, Armour CL, **Bosnic-Anticevich SZ**. (2005) Counseling about Turbuhaler technique: Needs assessment and effective strategies for community pharmacists. *Respiratory Care Journal*, 50(5); 617-623
166. Kritikos V, Saini B, **Bosnic-Anticevich SZ**, Krass I, Shah S, Taylor S, Armour C. (2005) Innovative asthma health promotion by rural community pharmacists: a feasibility study. *Health Promotion Journal of Australia*, 16 (1); 69-73
167. Kritikos V, Krass I, Chan, H, **Bosnic-Anticevich**. (2005). The Validity and Reliability of Two Asthma Knowledge Questionnaires. *Journal of Asthma*. 42: 795-801.

2004

168. Chew NYK, Reddel HK, **Bosnic-Anticevich SZ**, Chan HK (2004). Effect of Mouthpiece washing on aerosol performance of CFC-free Ventolin. *Journal of Asthma*. 41(7): 721-27.
169. Slader CA, Reddel HK, **Bosnic-Anticevich SZ** (2004). Lack of Awareness of Device Care for CFC-Free Metered Dose Inhalers. *Journal of Asthma*, 41(3): 367-373.
170. Slader C, Marks G, Ng K, Toelle B, Jenkins C, Armour C, Reddel H, **Bosnic-Anticevich S** (2004). Do Australians with asthma and wheeze use complementary and alternative medicine (CAM)? *Australian Pharmacist*, 23(2); 159.

2003

171. Kritikos V, Watt HMG, Krass I, Sainsbury EJ, **Bosnic-Anticevich SZ** (2003). Pharmacy Students' perception of their profession relative to other health care professions. *International Journal of Pharmacy Practice*, 11(2); 97-105

2002

172. Aslani P, **Bosnic-Anticevich S**, Sainsbury E, Koo M, Roberts A, Krass I. The 12th International Social Pharmacy Workshop: A report of the Teacher's workshop held in Sydney, Australia, 2002. *Pharmacy Education* 2(4), 213-219.
173. **Bosnic-Anticevich, S.** (2002). Facts behind the Fact Card. *InPharmation*, 6-11.
174. **Bosnic-Anticevich, S.** (2002). National prescribing service limited case study PH6. *Managing Asthma*.

175. Slader, C., Reddel, H., **Bosnic-Anticevich, S.** (2002). Use of CFC-free metered dose inhalers: do patients and pharmacists know what to do? *Australian Pharmacist*, 526-531.

1997

176. Armour CL, Johnson P, **Anticevich S**, Ammit A, McKay K, Hughes JM, Black JL (1997). Mediators on human airway smooth muscle. *Clinical and Experimental Pharmacology and Physiology*, 24, 269-272.

1996

177. **Anticevich SZ**, Hughes JM, Black JL, Armour CL (1996). The role of neutrophils and their products in the inflammatory process of asthma. *Australian Journal of Pharmacy*, 77, 846.
178. **Anticevich SZ**, Hughes JM, Black JL, Armour CL (1996). Induction of hyperresponsiveness in human way tissue by neutrophils - mechanism of action. *Clinical and Experimental Allergy*, 26, 549-556.

1995

179. **Anticevich SZ**, Hughes JM, Black JL, Armour CL, (1995). Induction of human airway hyperresponsiveness by tumour necrosis factor alpha. *European Journal of Pharmacology*, 284, 221-225.